(FILE 'HOME' ENTERED AT 14:29:59 ON 25 OCT 2001)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 14:30:20 ON 25 OCT 2001

```
L1         15519 S IGG4 OR (IMMUNE GLOBULIN IGG) OR IMMUNOGLOBULIN IGG
L2          1666 S PLASMA AND L1
L3           813 S L2 AND CONCENTRA?
L4           522 S L3 AND PREPAR?
L5           202 S L4 AND LYOPHILIZ?
L6           202 DUP REM L5 (0 DUPLICATES REMOVED)
L7            81 S L6 AND IGG4

=>
```

L7 ANSWER 1 OF 81 USPATFULL

ACCESSION NUMBER:	2001:184842 USPATFULL			
TITLE:	Fas antigen derivatives			
INVENTOR(S):	Nakamura, Norio, Tokyo, Japan Nagata, Shigekazu, Osaka-fu, Japan			
PATENT ASSIGNEE(S):	Mochida Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation) Osaka Bioscience Institute, Osaka, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6306395	B1	20011023	
	WO 9742319		19971113	
APPLICATION INFO.:	US 1998-180100		19981102	(9)
	WO 1997-JP1502		19970501	
			19981102	PCT 371 date
			19981102	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1996-135760		19960502	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Huff, Sheela			
ASSISTANT EXAMINER:	Harris, Alana M.			
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP			
NUMBER OF CLAIMS:	22			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 28 Drawing Page(s)			
LINE COUNT:	2004			

L7 ANSWER 2 OF 81 USPATFULL

ACCESSION NUMBER:	2001:173139 USPATFULL			
TITLE:	Method of treatment			
INVENTOR(S):	Whitfill, Craig E., Apex, NC, United States Thoma, John A., Fayetteville, AR, United States Fredericksen, Tommy L., Ashford, CT, United States Tyczkowski, Julius K., Cary, NC, United States Thaxton, Jr., J. Paul, Brandon, MS, United States			
PATENT ASSIGNEE(S):	University of Arkansas, Fayetteville, AR, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6299874	B1	20011009	
APPLICATION INFO.:	US 2000-613611		20000711	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-13760, filed on 27 Jan 1998, now patented, Pat. No. US 6136319 Continuation of Ser. No. US 1996-697268, filed on 21 Aug 1996, now patented, Pat. No. US 5871748 Continuation of Ser. No. US 1994-345291, filed on 28 Nov 1994, now abandoned Continuation of Ser. No. US 1993-8394, filed on 25 Jan 1993, now patented, Pat. No. US 5397569 Continuation of Ser. No. US 1990-586859, filed on 21 Sep 1990, now abandoned Continuation-in-part of Ser. No. US 1990-480678, filed on 15 Feb 1990, now abandoned Continuation-in-part of Ser. No. US 1989-416035, filed on 2 Oct 1989, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Nelson, Brett L.			
LEGAL REPRESENTATIVE:	Myers Bigel Sibley & Sajovec			
NUMBER OF CLAIMS:	116			

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1982

L7 ANSWER 3 OF 81 USPATFULL
ACCESSION NUMBER: 2001:171199 USPATFULL
TITLE: Anti-TNF antibodies and peptides of human tumor necrosis factor
INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Daddona, Peter, Menlo Park, CA, United States
Ghrayeb, John, Downingtown, PA, United States
Knight, David, Berwyn, PA, United States
Siegel, Scott, Westborough, MA, United States
PATENT ASSIGNEE(S): Centocor, Inc.,, Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001027249	A1	20011004
APPLICATION INFO.:	US 2001-756301	A1	20010108 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-133119, filed on 12 Aug 1998, PENDING Division of Ser. No. US 1995-570674, filed on 11 Dec 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-324799, filed on 18 Oct 1994, GRANTED, Pat. No. US 5698195 Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994, GRANTED, Pat. No. US 5656272 Continuation-in-part of Ser. No. US 1994-192861, filed on 4 Feb 1994, GRANTED, Pat. No. US 5919452 Continuation-in-part of Ser. No. US 1994-192093, filed on 4 Feb 1994, PENDING Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Carolyn S. Elmore, HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Page(s)
LINE COUNT: 5577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 81 USPATFULL
ACCESSION NUMBER: 2001:165585 USPATFULL
TITLE: Immunoassay technique using multispecific molecules
INVENTOR(S): Khaw, Ban-an, Milton, MA, United States
Narula, Jagat, Rosemont, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024795	A1	20010927
APPLICATION INFO.:	US 2000-727421	A1	20001201 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-380168, filed on 6 Oct 1999, PENDING

NUMBER	DATE

PRIORITY INFORMATION: US 1997-39111 19970226 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 81 USPATFULL
ACCESSION NUMBER: 2001:165438 USPATFULL
TITLE: Monkey monoclonal antibodies specific to human B7.1 and/or B7.2, primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants
INVENTOR(S): Anderson, Darrell R., Escondido, CA, United States
Brams, Peter, San Diego, CA, United States
Hanna, Nabil, Rancho Santa Fe, CA, United States
Shestowsky, William S., San Diego, CA, United States
Heard, Cheryl, Encinitas, CA, United States
PATENT ASSIGNEE(S): IDEC Pharmaceuticals Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024648	A1	20010927
APPLICATION INFO.:	US 2001-758173	A1	20010112 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-383916, filed on 26 Aug 1999, PENDING Division of Ser. No. US 1995-487550, filed on 7 Jun 1995, GRANTED, Pat. No. US 6113898
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP, Intellectual Property Group, East Tower, Ninth Floor, 1100 New York Avenue, N.W., Washington, DC, 20005-3918
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 1691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 81 USPATFULL
ACCESSION NUMBER: 2001:160973 USPATFULL
TITLE: Use of heregulin as a growth factor
INVENTOR(S): Sliwkowski, Mark X., San Carlos, CA, United States
Kern, Jeffrey A., Iowa City, IA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023241	A1	20010920
APPLICATION INFO.:	US 2001-773517	A1	20010202 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-243198, filed on 2 Feb 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-73866	19980204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 3786

L7 ANSWER 7 OF 81 USPATFULL
ACCESSION NUMBER: 2001:160802 USPATFULL
TITLE: Interleukins-21 and 22
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023070	A1	20010920
APPLICATION INFO.:	US 2000-731816	A1	20001208 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-320713, filed on 27 May 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US11644, filed on 27 May 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-87340	19980529 (60)
	US 1999-131965	19990430 (60)
	US 1999-169837	19991209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 7740

L7 ANSWER 8 OF 81 USPATFULL
ACCESSION NUMBER: 2001:155766 USPATFULL
TITLE: 49 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, United States
Ruben, Steven M., Oley, MD, United States
Olsen, Henrik S., Gaithersburg, MD, United States
Shi, Yanggu, Gaithersburg, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Florence, Kimberly A., Rockville, MD, United States
Soppet, Daniel R., Centreville, VA, United States
Lafleur, David W., Washington, DC, United States
Endress, Gregory A., Potomac, MD, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Komatsoulis, George, Silver Spring, MD, United States
Duan, Roxanne D., Bethesda, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001021700	A1	20010913
APPLICATION INFO.:	US 2000-739254	A1	20001219 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-511554, filed on 23 Feb 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-US19330, filed on 24 Aug 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97917	19980825 (60)
	US 1998-98634	19980831 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 15462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 81 USPATFULL
ACCESSION NUMBER: 2001:147682 USPATFULL
TITLE: Anti-TNFa antibodies and assays employing anti-TNFa antibodies
INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Dadonna, Peter, Palo Alto, CA, United States
Ghrayeb, John, Thorndale, PA, United States
Knight, David, Berwyn, PA, United States
Siegel, Scott A., Westborough, MA, United States
PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
Centocor, Inc., Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284471	B1	20010904
APPLICATION INFO.:	US 1994-192093		19940204 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Canella, Karen A.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 5032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 81 USPATFULL
ACCESSION NUMBER: 2001:142469 USPATFULL
TITLE: Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
INVENTOR(S): Laursen, Inga, Hellerup, Denmark
Teisner, B.o slashed.rge, Odense C, Denmark
PATENT ASSIGNEE(S): Statens Serum Institut, Copenhagen S., Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6281336	B1	20010828
APPLICATION INFO.:	US 1999-328497		19990609 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-201909	19980609
	US 1998-102055	19980928 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 1465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 81 USPATFULL
ACCESSION NUMBER: 2001:139293 USPATFULL
TITLE: Fibroblast growth factor receptor-5
INVENTOR(S): Young, Paul E., Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016335	A1	20010823
APPLICATION INFO.:	US 2001-758386	A1	20010112 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-293182, filed on 16 Apr 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-105465	19981023 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 6097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 81 USPATFULL
ACCESSION NUMBER: 2001:136770 USPATFULL
TITLE: Anti-TNF antibodies and peptides of human tumor necrosis factor
INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Daddona, Peter, Menlo Park, CA, United States
Ghrayeb, John, Thorndale, PA, United States
Knight, David, Berwyn, PA, United States
Siegel, Scott, Westborough, MA, United States
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
Centocor, Inc., Malvern, PA, United States (U.S. corporation)
New York University Medical Center, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277969	B1	20010821
APPLICATION INFO.:	US 1998-133119		19980812 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-570674, filed on 11 Dec 1995, now abandoned Continuation-in-part of Ser. No. US 1994-324799, filed on 18 Oct 1994, now patented, Pat. No. US 5698195, issued on 16 Dec 1997 Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994, now patented, Pat. No. US 5656272, issued on 12 Aug 1997 Continuation-in-part of Ser. No. US 1994-192861, filed on 4 Feb 1994, now patented, Pat. No. US 5919452, issued on 6 Jul 1999 Continuation-in-part of Ser. No. US 1994-192093, filed

on 4 Feb 1994 Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Canella, Karen
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 5429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 81 USPATFULL
ACCESSION NUMBER: 2001:136184 USPATFULL
TITLE: Immunoglobulin-like domains with increased half-lives
INVENTOR(S): Ward, Elizabeth Sally, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6277375	B1	20010821	
APPLICATION INFO.:	US 1997-811463		19970303	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Fulbright & Jaworski
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 4495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 81 USPATFULL
ACCESSION NUMBER: 2001:102968 USPATFULL
TITLE: High affinity human antibodies and human antibodies against digoxin
INVENTOR(S): Lonberg, Nils, Woodside, CA, United States
Kay, Robert M., San Francisco, CA, United States
PATENT ASSIGNEE(S): GenPharm International, San Jose, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6255458	B1	20010703	
APPLICATION INFO.:	US 1998-42353		19980313	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-758417, filed on 2 Dec 1996 Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996 Continuation-in-part of Ser. No. US 1995-544404, filed on 10 Oct 1995, now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US 1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126 Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned

Continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993, now patented, Pat. No. US 5814318 Continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US 5789650 Continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 5633425 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: DiBrino, Marianne
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 119 Drawing Figure(s); 103 Drawing Page(s)
LINE COUNT: 10059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 81 USPATFULL
ACCESSION NUMBER: 2001:97420 USPATFULL
TITLE: Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
INVENTOR(S): Gallatin, W. Michael, 8412 SE. 33rd Pl., Mercer Island, WA, United States 98040
Van der Vieren, Monica, 2446 NW. 64th St., Seattle, WA, United States 98107

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251395	B1	20010626
APPLICATION INFO.:	US 1998-193043		19981116 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-943363, filed on 3 Oct 1997, now patented, Pat. No. US 5837478, issued on 17 Nov 1998 Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996, now patented, Pat. No. US 5817515, issued on 6 Oct 1998 Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994, now patented, Pat. No. US 5766850, issued on 16 Jun 1998 Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953, issued on 28 Nov 1995 Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958, issued on 1 Aug 1995

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gambel, Phillip
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 6697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 81 USPATFULL
ACCESSION NUMBER: 2001:67171 USPATFULL
TITLE: Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
INVENTOR(S): Co, Man Sung, Cupertino, CA, United States
Vasquez, Maximiliano, Palo Alto, CA, United States
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228360	B1	20010508
APPLICATION INFO.:	US 1998-136315		19980819 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 81 USPATFULL
ACCESSION NUMBER: 2001:47546 USPATFULL
TITLE: Humanized antibodies reactive with L-selectin
INVENTOR(S): Co, Man Sung, Cupertino, CA, United States
PATENT ASSIGNEE(S): Protein Design Labs, Inc., Fremont, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6210671	B1	20010403
APPLICATION INFO.:	US 1995-579378		19951227 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-160074, filed on 30 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1992-983946, filed on 1 Dec 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-112895	19950817
	EP 1995-114696	19950919

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1,13,15
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 81 USPATFULL
ACCESSION NUMBER: 2001:47545 USPATFULL
TITLE: Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
INVENTOR(S): Berg, Ellen L., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Protein Design Labs, Inc., Fremont, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6210670	B1	20010403	
	WO 9534324		19951221	
APPLICATION INFO.:	US 1996-619491		19960326	(8)
	WO 1995-US7302		19950607	
			19960326	PCT 371 date
			19960326	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-259963, filed on 14 Jun 1994, now patented, Pat. No. US 5622701
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew LLP, Storella, John
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1,15
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 81 USPATFULL
ACCESSION NUMBER: 2001:4887 USPATFULL
TITLE: Anti-IgE antibodies and method of improving polypeptides
INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6172213	B1	20010109	
APPLICATION INFO.:	US 1998-109207		19980630	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-51554	19970702	(60)

DOCUMENT TYPE: Patent
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Ewoldt, Gerald R.
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 81 USPATFULL
ACCESSION NUMBER: 2000:168146 USPATFULL
TITLE: Anti-human .alpha..sub.v .beta..sub.3 and .alpha..sub.v .beta..sub.5 antibodies
INVENTOR(S): Jonak, Zdenka Ludmila, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Taylor, Alexander, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Trulli, Stephen H, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939

Johanson, Kyung O, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6160099		20001212
APPLICATION INFO.:	US 1998-199149		19981124 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Helms, Larry R.
LEGAL REPRESENTATIVE: Baumeister, Kirk, King, William T.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 81 USPATFULL
ACCESSION NUMBER: 2000:167510 USPATFULL
TITLE: Uses of Wnt polypeptides
INVENTOR(S): Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159462		20001212
APPLICATION INFO.:	US 1997-911860		19970815 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24068	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Svoboda, Craig G., Carpenter, David A.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 81 USPATFULL
ACCESSION NUMBER: 2000:157557 USPATFULL
TITLE: Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
INVENTOR(S): Murphy, Gerald P., Seattle, WA, United States
Boynton, Alton L., Redmond, WA, United States
Holmes, Eric H., Bothell, WA, United States
Tino, William Thomas, Redmond, WA, United States
PATENT ASSIGNEE(S): Northwest Biotherapeutics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150508		20001121
APPLICATION INFO.:	US 1998-44668		19980318 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-827017, filed on 25 Mar 1997, now abandoned which is a continuation-in-part of Ser. No. US 1996-621399, filed

on 25 Mar 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ungar, Susan
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,2,7,12
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT: 1896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 81 USPATFULL
ACCESSION NUMBER: 2000:146146 USPATFULL
TITLE: Cell-targeting molecule comprising a mutant human carboxypeptidase A
INVENTOR(S): Smith, Gary Keith, Raleigh, NC, United States
Blumenkopf, Todd Andrew, Old Lyme, CT, United States
Cory, Michael, Chapel Hill, NC, United States
PATENT ASSIGNEE(S): Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6140100		20001031	
	WO 9513095		19950518	
APPLICATION INFO.:	US 1996-640906		19960509	(8)
	WO 1994-GB2483		19941111	
			19960509	PCT 371 date
			19960509	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-23429	19931112

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Moore, William W.
LEGAL REPRESENTATIVE: Grassler, Frank P., Bennett, Virginia C., Hrubiec, Robert T.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 7473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 81 USPATFULL
ACCESSION NUMBER: 2000:141887 USPATFULL
TITLE: Method of treating viral diseases in animals
INVENTOR(S): Whitfill, Craig E., Apex, NC, United States
Thoma, John A., Fayetteville, AR, United States
Fredericksen, Tommy L., Ashford, CT, United States
Tyczkowski, Julius K., Cary, NC, United States
Thaxton, Jr., J. Paul, Brandon, MS, United States
PATENT ASSIGNEE(S): The University of Arkansas, Fayetteville, AR, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6136319		20001024	
APPLICATION INFO.:	US 1998-13760		19980127	(9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-697268, filed on 21 Aug 1996, now patented, Pat. No. US 5871748 which is a continuation of Ser. No. US 1994-345291, filed on 28 Nov 1994, now abandoned which is a continuation of Ser.

No. US 1993-8394, filed on 25 Jan 1993, now patented, Pat. No. US 5397569 which is a continuation of Ser. No. US 1990-586859, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-480678, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-416035, filed on 2 Oct 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stucker, Jeffrey
ASSISTANT EXAMINER: Nelson, Brett
LEGAL REPRESENTATIVE: Myers Bigel Sibley & Sajovec
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1766
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 81 USPATFULL
ACCESSION NUMBER: 2000:141878 USPATFULL
TITLE: Recombinant anti-CD4 antibodies for human therapy
INVENTOR(S): Hanna, Nabil, Olivenhain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliot, San Diego, CA, United States
PATENT ASSIGNEE(S): IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6136310		20001024
APPLICATION INFO.:	US 1995-523894		19950906 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995, now patented, Pat. No. US 5756096 which is a continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 3398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 81 USPATFULL
ACCESSION NUMBER: 2000:124800 USPATFULL
TITLE: Altered polypeptides with increased half-life
INVENTOR(S): Presta, Leonard G., San Francisco, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121022		20000919
APPLICATION INFO.:	US 1995-422112		19950414 (8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Lee, WendyFlehr Hohabch Test Albritton & Herbert LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 3411
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 81 USPATFULL
ACCESSION NUMBER: 2000:117279 USPATFULL
TITLE: Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
INVENTOR(S): Anderson, Darrell R., Escondido, CA, United States
Brams, Peter, San Diego, CA, United States
Hanna, Nabil, Rancho Santa Fe, CA, United States
Shestowsky, William S., San Diego, CA, United States
Heard, Cheryl, Encinitas, CA, United States
PATENT ASSIGNEE(S): IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6113898		20000905	
APPLICATION INFO.:	US 1995-487550		19950607	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 81 USPATFULL
ACCESSION NUMBER: 2000:98553 USPATFULL
TITLE: Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
INVENTOR(S): Presta, Leonard G., San Francsico, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6096871		20000801	
APPLICATION INFO.:	US 1995-422093		19950414	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reeves, Julie
LEGAL REPRESENTATIVE: Hasak, Jan, Vance, Dolly A.Flehr Hohbach Test Albritton & Herbert LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 3391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 81 USPATFULL
ACCESSION NUMBER: 2000:70963 USPATFULL
TITLE: Reshaped monoclonal antibodies against an immunoglobulin isotype

INVENTOR(S): Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6072035		20000606
APPLICATION INFO.:	US 1995-485246		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-127721, filed on 27 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reeves, Julie
LEGAL REPRESENTATIVE: Ferraro, Gregory D.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 81 USPATFULL
ACCESSION NUMBER: 2000:64943 USPATFULL
TITLE: Reshaped monoclonal antibodies against an immunoglobulin isotype
INVENTOR(S): Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066718		20000523
APPLICATION INFO.:	US 1993-127721		19930927 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Worrall, Timothy A.
LEGAL REPRESENTATIVE: Ferrar, Gregory D.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 81 USPATFULL
ACCESSION NUMBER: 2000:46884 USPATFULL
TITLE: Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
INVENTOR(S): Allison, James Patrick, Berkeley, CA, United States
Leach, Dana R., Albany, CA, United States
Krummel, Matthew F., Berkeley, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Office of

Technology Transfer, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051227		20000418
APPLICATION INFO.:	US 1996-760288		19961204 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-646605, filed on 8 May 1996, now patented, Pat. No. US 5811097 which is a continuation-in-part of Ser. No. US 1995-566853, filed on 4 Dec 1995, now patented, Pat. No. US 5855887 which is a continuation-in-part of Ser. No. US 1995-506666, filed on 25 Jul 1995, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Trecartin, Richard F., Lorenz, Todd A.Flehr Hohbach Test Albritton & Herbert LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 32 OF 81 USPATFULL
ACCESSION NUMBER: 2000:27563 USPATFULL
TITLE: Method for detecting the presence of P-selectin
INVENTOR(S): Chesnut, Robert W., Cardiff, CA, United States
Polley, Margaret J., La Jolla, CA, United States
Paulson, James C., Del Mar, CA, United States
Jones, S. Tarran, Radlett, United Kingdom
Saldanha, Jose W., Middlesex, United Kingdom
Bendig, Mary M., London, United Kingdom
Kriegler, Michael, Rancho Santa Fe, CA, United States
Perez, Carl, San Diego, CA, United States
Bayer, Robert, San Diego, CA, United States
Nunn, Michael, San Diego, CA, United States
PATENT ASSIGNEE(S): Cytel Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6033667		20000307
APPLICATION INFO.:	US 1997-964690		19971105 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-202047, filed on 25 Feb 1994, now patented, Pat. No. US 5800815 which is a continuation-in-part of Ser. No. US 1993-57292, filed on 5 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-880196, filed on 5 May 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1993-105614	19930505

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 4009
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 81 USPATFULL

ACCESSION NUMBER:	2000:12616 USPATFULL
TITLE:	Chimeric antibodies
INVENTOR(S):	Hardman, Norman, Riehen, Switzerland Gill, Laura Lee, Riehen, Switzerland de Winter, Ronald F. J., Milton Ernest, United Kingdom Wagner, Kathrin, Basel, Switzerland Heusser, Christoph, Bottmingen, Switzerland
PATENT ASSIGNEE(S):	Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6020153		20000201	
APPLICATION INFO.:	US 1994-307087		19940916	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-947897, filed on 18 Sep 1992, now abandoned which is a continuation of Ser. No. US 1988-287178, filed on 21 Dec 1988, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-77	19880105
	GB 1988-20099	19880824

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Ziska, Suzanne E.
LEGAL REPRESENTATIVE:	Nowak, Henry P., Elmer, James Scott, Foley, Shawn P.
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT:	2592

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 81 USPATFULL

ACCESSION NUMBER:	2000:10021 USPATFULL
TITLE:	Antibody against human interleukin-5-receptor .alpha. chain
INVENTOR(S):	Koike, Masamichi, Tokyo, Japan Furuya, Akiko, Tokyo, Japan Nakamura, Kazuyasu, Tokyo, Japan Iida, Akihiro, Tokyo, Japan Anazawa, Hideharu, Tokyo, Japan Hanai, Nobuo, Kanagawa, Japan Takatsu, Kiyoshi, Tokyo, Japan
PATENT ASSIGNEE(S):	Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6018032		20000125	
	WO 9710354		19970320	
APPLICATION INFO.:	US 1997-836561		19970509	(8)
	WO 1996-JP2588		19960911	
			19970509	PCT 371 date
			19970509	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-232384	19950911

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Mertz, Prema
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 61 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 5703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 81 USPATFULL
ACCESSION NUMBER: 1999:163215 USPATFULL
TITLE: Humanized antibodies to human gp39, compositions containing thereof
INVENTOR(S): Black, Amelia, Cardiff, CA, United States
Hanna, Nabil, Olivenhian, CA, United States
Padlan, Eduardo A., Kensington, MD, United States
Newman, Roland A., San Diego, CA, United States
PATENT ASSIGNEE(S): Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6001358		19991214	
APPLICATION INFO.:	US 1995-554840		19951107	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 81 USPATFULL
ACCESSION NUMBER: 1999:155894 USPATFULL
TITLE: Anti-IgE antibodies and methods of improving polypeptides
INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5994511		19991130	
APPLICATION INFO.:	US 1997-887352		19970702	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 5816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 81 USPATFULL
ACCESSION NUMBER: 1999:136684 USPATFULL
TITLE: Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
INVENTOR(S): Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States

PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976534		19991102
APPLICATION INFO.:	US 1995-482533		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-366860, filed on 30 Dec 1994, now patented, Pat. No. US 5620687 which is a continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Parker, Gary E.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 81 USPATFULL
ACCESSION NUMBER: 1999:117280 USPATFULL
TITLE: Reshaped monoclonal antibodies against an immunoglobulin isotype
INVENTOR(S): Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5958708		19990928
APPLICATION INFO.:	US 1995-476176		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-127721, filed on 27 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Navarro, Mark
LEGAL REPRESENTATIVE: Ferraro, Gregory D.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 81 USPATFULL
ACCESSION NUMBER: 1999:85255 USPATFULL
TITLE: DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
INVENTOR(S): Holmes, Stephen D., Epsom, United Kingdom
Gross, Mitchell Stuart, Wayne, PA, United States
Sylvester, Daniel R., Phoenixville, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

SmithKline Beecham P.L.C., Brentford, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5928904		19990727
APPLICATION INFO.:	US 1995-483632		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1994-US10308, filed on 7 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-136783, filed on 14 Oct 1993, now abandoned which is a continuation of Ser. No. US 1993-117366, filed on 7 Sep 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Navarro, Mark
LEGAL REPRESENTATIVE: Eagle, Alissa M., King, William T., Venetianer, Stephen
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 40 OF 81 USPATFULL
ACCESSION NUMBER: 1999:81543 USPATFULL
TITLE: Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
INVENTOR(S): Browning, Jeffrey L., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Brookline, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925351		19990720
APPLICATION INFO.:	US 1995-505606		19950721 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Biogen, Inc., Flynn, Kerry A.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,15
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 41 OF 81 USPATFULL
ACCESSION NUMBER: 1999:75310 USPATFULL
TITLE: Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF antibodies
INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Dadonna, Peter, Palo Alto, CA, United States
Ghrayeb, John, Thorndale, PA, United States
Knight, David, Berwyn, PA, United States
Seigal, Scott, Westborough, MA, United States
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
Centocor, Inc., Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919452		19990706
APPLICATION INFO.:	US 1994-192861		19940204 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 5351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 42 OF 81 USPATFULL
ACCESSION NUMBER: 1999:69500 USPATFULL
TITLE: Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
INVENTOR(S): Holmes, Stephen D., Epsom, United Kingdom
Gross, Mitchell Stuart, Wayne, PA, United States
Sylvester, Daniel R., Phoenixville, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham p.l.c., Brentford, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914110		19990622
APPLICATION INFO.:	US 1995-483636		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1994-US10308, filed on 7 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-136783, filed on 14 Oct 1993, now abandoned which is a continuation of Ser. No. US 1993-117366, filed on 7 Sep 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Navarro, Mark
LEGAL REPRESENTATIVE: Eagle, Alissa M., King, William T., Venetianer, Stephen
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 43 OF 81 USPATFULL
ACCESSION NUMBER: 1999:21735 USPATFULL
TITLE: Method of treating viral diseases in animals
INVENTOR(S): Whitfill, Craig E., Apex, NC, United States
Thoma, John A., Fayetteville, AR, United States
Fredericksen, Tommy L., Ashford, CT, United States
Tyczkowski, Julius K., Cary, NC, United States

Thaxton, Jr., J. Paul, Brandon, MS, United States
PATENT ASSIGNEE(S): Embrex, Inc, Research Triangle Park, NC, United States (U.S. corporation)
The University of Arkansas, Fayetteville, AR, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5871748		19990216
APPLICATION INFO.:	US 1996-697268		19960821 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-345291, filed on 28 Nov 1994, now abandoned which is a continuation of Ser. No. US 1993-8394, filed on 25 Jan 1993, now patented, Pat. No. US 5397569 which is a continuation of Ser. No. US 1990-586859, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-480678, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-416035, filed on 2 Oct 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Smith, Lynette F.
ASSISTANT EXAMINER: Nelson, Brett L.
LEGAL REPRESENTATIVE: Myers Bigel Sibley & Sajovec, LLP
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 44 OF 81 USPATFULL
ACCESSION NUMBER: 1999:18720 USPATFULL
TITLE: Altered polypeptides with increased half-life
INVENTOR(S): Presta, Leonard G., San Francsico, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869046		19990209
APPLICATION INFO.:	US 1995-422092		19950414 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
ASSISTANT EXAMINER: Rabin, Evelyn
LEGAL REPRESENTATIVE: Dreger, Walter H.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 3287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 45 OF 81 USPATFULL
ACCESSION NUMBER: 1999:4367 USPATFULL
TITLE: DNA encoding an insulin receptor substrate
INVENTOR(S): White, Morris F., West Roxbury, MA, United States
Sun, Xiao Jian, Boston, MA, United States
Pierce, Jacalyn H., Potomac, MD, United States
PATENT ASSIGNEE(S): Joslin Diabetes Center, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 5858701	19990112
APPLICATION INFO.:	US 1994-317310	19941003 (8)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hutzell, Paula K.	
ASSISTANT EXAMINER:	Hayes, Robert C.	
LEGAL REPRESENTATIVE:	Myers, Esq., Louis	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 27 Drawing Page(s)	
LINE COUNT:	2713	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 46 OF 81 USPATFULL

ACCESSION NUMBER:	1998:159916 USPATFULL
TITLE:	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
INVENTOR(S):	Matthews, William, Woodside, CA, United States Austin, Timothy W., Morgan Hill, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5851984		19981222	
APPLICATION INFO.:	US 1996-696566		19960816	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Fitzgerald, David L.			
ASSISTANT EXAMINER:	Basham, Daryl A.			
LEGAL REPRESENTATIVE:	Svoboda, Craig G., Marschang, Diane L.			
NUMBER OF CLAIMS:	20			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	3923			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 47 OF 81 USPATFULL

ACCESSION NUMBER:	1998:153858 USPATFULL
TITLE:	Antibodies to the antigen campath-1
INVENTOR(S):	Waldmann, Herman, Cambridge, United Kingdom Clark, Michael R., Cambridge, United Kingdom Winter, Gregory P., Cambridge, United Kingdom Riechmann, Lutz, La Jolla, CA, United States
PATENT ASSIGNEE(S):	British Technology Group Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5846534		19981208	
APPLICATION INFO.:	US 1994-235705		19940429	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-99480, filed on 30 Jul 1993, now abandoned which is a continuation of Ser. No. US 1992-921601, filed on 3 Aug 1992, now abandoned which is a continuation of Ser. No. US 1989-424233, filed on 12 Oct 1989, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-3228	19880212
	GB 1988-4464	19880225
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Budens, Robert D.	

LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1,13
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 48 OF 81 USPATFULL
ACCESSION NUMBER: 1998:150724 USPATFULL
TITLE: Chimeric antibodies
INVENTOR(S): Hardman, Norman, Riehen, Switzerland
Gill, Laura Lee, Riehen, Switzerland
de Winter, Ronald F.J., Milton Ernest, England
Wagner, Kathrin, Basel, Switzerland
Heusser, Christoph, Bottmingen, Switzerland
PATENT ASSIGNEE(S): CIBA-GEIGY Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843708		19981201
APPLICATION INFO.:	US 1995-462371		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-307087, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1992-947897, filed on 18 Sep 1992, now abandoned which is a continuation of Ser. No. US 1988-287178, filed on 21 Dec 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-77	19880105
	GB 1988-20099	19880824

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ziska, Suzanne E.
LEGAL REPRESENTATIVE: Nowak, Henry P.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 49 OF 81 USPATFULL
ACCESSION NUMBER: 1998:150462 USPATFULL
TITLE: Cellular and serum protein anchors for modulating pharmacokinetics
INVENTOR(S): Pouletty, Philippe, Atherton, CA, United States
Pouletty, Christine, Atherton, CA, United States
PATENT ASSIGNEE(S): RedCell Canada, Inc., Montreal, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843440		19981201
APPLICATION INFO.:	US 1996-702127		19960814 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-137821, filed on 15 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-70092, filed on 27 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-592214, filed on 3 Oct 1990, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Johnson, Nancy A.

LEGAL REPRESENTATIVE: Limbach & Limbach L.L.P.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 50 OF 81 USPATFULL
ACCESSION NUMBER: 1998:143883 USPATFULL
TITLE: Method of identifying modulators of binding between and VCAM-1
INVENTOR(S): Gallatin, W. Michael, Mercer Island, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837478		19981117
APPLICATION INFO.:	US 1997-943363		19971003 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996 which is a continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994, now patented, Pat. No. US 5766850 which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953, issued on 28 Nov 1995 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958, issued on 1 Aug 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 7878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 51 OF 81 USPATFULL
ACCESSION NUMBER: 1998:135170 USPATFULL
TITLE: Human .beta.2 integrin .alpha. subunit
INVENTOR(S): Gallatin, W. Michael, Mercer Island, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5831029		19981103
APPLICATION INFO.:	US 1995-482293		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
ASSISTANT EXAMINER: Rabin, Evelyn
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 5481
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 52 OF 81 USPATFULL
ACCESSION NUMBER: 1998:122270 USPATFULL
TITLE: Human B2 integrin alpha subunit antibodies
INVENTOR(S): Gallatin, W. Michael, Mercer Island, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817515		19981006
APPLICATION INFO.:	US 1996-605672		19960222 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953, issued on 28 Nov 1995 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958, issued on 1 Aug 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 6188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 53 OF 81 USPATFULL
ACCESSION NUMBER: 1998:115416 USPATFULL
TITLE: Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
INVENTOR(S): Allison, James Patrick, Berkeley, CA, United States
Leach, Dana R., Albany, CA, United States
Krummel, Matthew F., Berkeley, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5811097		19980922
APPLICATION INFO.:	US 1996-646605		19960508 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-566853, filed on 4 Dec 1995 which is a continuation-in-part of Ser. No. US 1995-506666, filed on 25 Jul 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Lucas, John
LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert, LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 54 OF 81 USPATFULL
ACCESSION NUMBER: 1998:104391 USPATFULL

TITLE: Antibodies to P-selectin and their uses
INVENTOR(S): Chestnut, Robert W., Cardiff, CA, United States
Polley, Margaret J., La Jolla, CA, United States
Paulson, James C., Del Mar, CA, United States
Jones, S. Tarran, Radlett, United Kingdom
Saldanha, Jose W., Middlesex, United Kingdom
Bendig, Mary M., London, United Kingdom
Kriegler, Michael, Rancho Santa Fe, CA, United States
Perez, Carl, San Diego, CA, United States
Bayer, Robert, San Diego, CA, United States
Nunn, Michael, San Diego, CA, United States
PATENT ASSIGNEE(S): Cytel Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800815		19980901
APPLICATION INFO.:	US 1994-202047		19940225 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-57292, filed on 5 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-880198, filed on 5 May 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1903-105614	19030505
	WO 1993-US4274	19930504

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 32,40
NUMBER OF DRAWINGS: 47 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 4013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 55 OF 81 USPATFULL
ACCESSION NUMBER: 1998:82874 USPATFULL
TITLE: Monoclonal antibodies to cytotoxic lymphocyte maturation factor
INVENTOR(S): Gately, Maurice Kent, Montville, NJ, United States
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States
Hulmes, Jeffrey David, Ringwood, NJ, United States
Podlaski, Frank John, New City, NY, United States
Stern, Alvin Seth, Passaic Park, NJ, United States
Chizzonite, Richard Anthony, South Kent, CT, United States
Pan, Yu-Ching Eugene, Pine Brook, NJ, United States
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780597		19980714
APPLICATION INFO.:	US 1995-460061		19950602 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-205011, filed on 2 Mar 1994, now abandoned which is a division of Ser. No. US 1992-857023, filed on 24 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-572284, filed on 27 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-520935, filed on 9 May 1990, now abandoned which is a

continuation-in-part of Ser. No. US 1989-455708, filed on 22 Dec 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
ASSISTANT EXAMINER: Lubet, Martha T.
LEGAL REPRESENTATIVE: Johnston, George W., Epstein, William H., Buchholz, Briana C.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 2912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 56 OF 81 USPATFULL
ACCESSION NUMBER: 1998:82339 USPATFULL
TITLE: Methods of treatment of down syndrome by interferon antagonists
INVENTOR(S): Maroun, Leonard E., Springfield, IL, United States
PATENT ASSIGNEE(S): Meiogen Biotechnology Corporation, Springfield, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780027		19980714
APPLICATION INFO.:	US 1995-502519		19950714 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 777
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 57 OF 81 USPATFULL
ACCESSION NUMBER: 1998:68777 USPATFULL
TITLE: Human .beta.2 integrin .alpha. subunit
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5766850		19980616
APPLICATION INFO.:	US 1994-362652		19941221 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Furman, Keith C.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 58 OF 81 USPATFULL

ACCESSION NUMBER: 1998:47965 USPATFULL
TITLE: Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
INVENTOR(S): Presta, Leonard G., San Francsico, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5747035		19980505	
APPLICATION INFO.:	US 1995-422091		19950414	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Dreger, Walter H.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 3305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 59 OF 81 USPATFULL
ACCESSION NUMBER: 1998:39666 USPATFULL
TITLE: Altered polypeptides with increased half-life
INVENTOR(S): Presta, Leonard G., San Francisco, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Genentech Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5739277		19980414	
APPLICATION INFO.:	US 1995-422101		19950414	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1,2,3
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 3251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 60 OF 81 USPATFULL
ACCESSION NUMBER: 1998:27915 USPATFULL
TITLE: Human .beta..sub.2 integrin .alpha.subunit
INVENTOR(S): Gallatin, W. Michael, Mercer Island, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5728533		19980317	
APPLICATION INFO.:	US 1995-485618		19950607	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen C.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 61 OF 81 USPATFULL
ACCESSION NUMBER: 97:118165 USPATFULL
TITLE: Product and process for targeting an immune response
INVENTOR(S): Nemazee, David A., Denver, CO, United States
PATENT ASSIGNEE(S): National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5698679		19971216	
APPLICATION INFO.:	US 1994-309006		19940919	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Sheridan Ross P.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 62 OF 81 USPATFULL
ACCESSION NUMBER: 97:117693 USPATFULL
TITLE: Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Daddona, Peter, Menlo Park, CA, United States
Ghrayeb, John, Thorndale, PA, United States
Knight, David, Berwyn, PA, United States
Siegel, Scott, Westborough, MA, United States
PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
Centocor, Inc., Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5698195		19971216	
APPLICATION INFO.:	US 1994-324799		19941018	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994 Ser. No. Ser. No. US 1994-192061, filed on 4 Feb 1994, now abandoned And Ser. No. US 1994-192093, filed on 4 Feb 1994, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Lucas, John
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 5887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 63 OF 81 USPATFULL
ACCESSION NUMBER: 97:114931 USPATFULL
TITLE: Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
INVENTOR(S): Faanes, Ronald Bertrand, Pound Ridge, NY, United States
McGoff, Paul Edward, Watertown, CT, United States
Shirley, Bret Allen, New Milford, CT, United States
Scher, David Stuart, Danbury, CT, United States
PATENT ASSIGNEE(S): Boehringer Inglehiem Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5695760		19971209
APPLICATION INFO.:	US 1995-427355		19950424 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Howrey & Simon, Auerbach, Jeffery I.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1,12,24
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 64 OF 81 USPATFULL
ACCESSION NUMBER: 97:78179 USPATFULL
TITLE: Monoclonal antibody compositions cross-reactive and cross-protective against P. aeruginosa serotypes
INVENTOR(S): Siadak, Anthony W., Seattle, WA, United States
Rosok, Mae J., Seattle, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5662905		19970902
APPLICATION INFO.:	US 1994-366204		19941229 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-66604, filed on 24 May 1993, now patented, Pat. No. US 5378812 which is a continuation of Ser. No. US 1986-931179, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-807394, filed on 10 Dec 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Townsend And Townsend And Crew LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 65 OF 81 USPATFULL

ACCESSION NUMBER: 97:70718 USPATFULL

TITLE: Methods of treating TNF-.alpha.-mediated Crohn's disease using chimeric anti-TNF antibodies

INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
Vilcek, Jan, New York, NY, United States
Dadonna, Peter, Palo Alto, CA, United States
Ghrayeb, John, Thorndale, PA, United States
Knight, David, Berwyn, PA, United States
Siegel, Scott A., Westborough, MA, United States

PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
Centocor, Inc., Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656272		19970812
APPLICATION INFO.:	US 1994-192102		19940204 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 26 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Lucas, John
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 5251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 66 OF 81 USPATFULL

ACCESSION NUMBER: 97:40481 USPATFULL

TITLE: Method for inhibiting the viability of Pseudomonas aeruginosa with cross-reactive and cross-protective monoclonal antibodies

INVENTOR(S): Siadak, Anthony W., Seattle, WA, United States
Rosok, Mae J., Seattle, WA, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5628996		19970513
APPLICATION INFO.:	US 1995-463910		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-366204, filed on 29 Dec 1994 which is a continuation of Ser. No. US 1993-66604, filed on 24 May 1993, now patented, Pat. No. US 5378812 which is a continuation of Ser. No. US 1986-931179, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-807394, filed on 10 Dec 1985, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Housel, James C.

ASSISTANT EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 67 OF 81 USPATFULL
ACCESSION NUMBER: 97:38410 USPATFULL
TITLE: Monoclonal antibodies cross-reactive and cross-protective against human monoclonal antibodies against pseudomonas aeruginosa serotypes
INVENTOR(S): Siadak, Anthony W., Seattle, WA, United States
Rosok, Mae J., Seattle, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627067		19970506
APPLICATION INFO.:	US 1995-462370		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-366204, filed on 29 Dec 1994 which is a continuation of Ser. No. US 1993-66604, filed on 24 May 1993, now patented, Pat. No. US 5378812 which is a continuation of Ser. No. US 1986-931179, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-807394, filed on 10 Dec 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 1391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 68 OF 81 USPATFULL
ACCESSION NUMBER: 97:31409 USPATFULL
TITLE: Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
INVENTOR(S): Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5620687		19970415
APPLICATION INFO.:	US 1994-366860		19941230 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Parker, Gary E., Leith, Debra K., Sawislak, Deborah A.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 69 OF 81 USPATFULL
ACCESSION NUMBER: 97:6049 USPATFULL
TITLE: Method of refolding human IL-13
INVENTOR(S): Culpepper, Janice, Mountain View, CA, United States
McKenzie, Andrew, Redwood City, CA, United States
Dang, Warren, San Jose, CA, United States
Zurawski, Gerard, Redwood City, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5596072		19970121
APPLICATION INFO.:	US 1993-12543		19930201 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-933416, filed on 21 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Spector, Lorraine M.
LEGAL REPRESENTATIVE: Ching, Edwin P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 288 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 4619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 70 OF 81 USPATFULL
ACCESSION NUMBER: 97:3527 USPATFULL
TITLE: Method of producing an anti-D immunoglobulin **concentrate** and a pharmaceutical **preparation**
INVENTOR(S): Hodler, Gerhard, Worb, Switzerland
Lerch, Peter, Bern, Switzerland
Stucki, Martin, Laupen, Switzerland
PATENT ASSIGNEE(S): Rotkreuzstiftung Zentrallaboratorium Blutspendedienst, Bern, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5593675		19970114
APPLICATION INFO.:	US 1994-360334		19941221 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1993-93810912	19931227

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 71 OF 81 USPATFULL
ACCESSION NUMBER: 96:82450 USPATFULL
TITLE: Methods and vaccines comprising surface-active copolymers

INVENTOR(S): Hunter, Robert L., Tucker, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5554372		19960910
APPLICATION INFO.:	US 1995-420333		19950411 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-133760, filed on 7 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-716807, filed on 21 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-544831, filed on 27 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-449086, filed on 8 Dec 1989, now abandoned which is a continuation of Ser. No. US 1989-341315, filed on 21 Apr 1989, now abandoned which is a continuation of Ser. No. US 1988-208335, filed on 17 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-75187, filed on 16 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-909964, filed on 22 Sep 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Housel, James C.
ASSISTANT EXAMINER: Shaver, Jennifer
LEGAL REPRESENTATIVE: Jones & Askew
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 72 OF 81 USPATFULL
ACCESSION NUMBER: 95:105943 USPATFULL
TITLE: Human .beta..sub.2 integrin .alpha. subunit
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5470953		19951128
APPLICATION INFO.:	US 1994-286889		19940805 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Kim, Hyosuk
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 5
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 73 OF 81 USPATFULL
ACCESSION NUMBER: 95:22692 USPATFULL
TITLE: Method of treating Infectious Bursal Disease Virus infections
INVENTOR(S): Whitfill, Craig E., 1300 Wellstone Cir., Apex, NC, United States 27502

Thomas, John A., 1206 Crestwood Dr., Fayetteville, AR, United States 72701
Fredericksen, Tommy L., 591 Westford Rd., Ashford, CT, United States 06278
Tyczkowski, Julius K., 111 Woodruff Ct., Cary, NC, United States 27511
Thaxton, Jr., J. Paul, 117 Campfire Cir., Brandon, MS, United States 39240

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5397569		19950314
APPLICATION INFO.:	US 1993-8394		19930125 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-586859, filed on 21 Sep 1990 which is a continuation-in-part of Ser. No. US 1990-480678, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-416035, filed on 2 Oct 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Krsek-Staples, Julie
LEGAL REPRESENTATIVE: Bell, Seltzer, Park & Gibson
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 74 OF 81 USPATFULL
ACCESSION NUMBER: 95:22691 USPATFULL
TITLE: Method of treating infectious bursal disease virus infections
INVENTOR(S): Whitfill, Craig E., 1300 Wellstone Cir., Apex, NC, United States 27502
Thoma, John A., 1206 Crestwood Dr., Fayetteville, AR, United States 72701
Fredericksen, Tommy L., 591 Westford Rd., Ashford, CT, United States 06278
Tyczkowski, Julius K., 111 Woodruff Ct., Cary, NC, United States 27511
Thaxton, Jr., J. Paul, 117 Campfire Cir., Brandon, MS, United States 39240

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5397568		19950314
APPLICATION INFO.:	US 1993-24093		19930225 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-591523, filed on 1 Oct 1990 which is a continuation-in-part of Ser. No. US 1990-480678, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-416035, filed on 2 Oct 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Krsek-Staples, Julie
LEGAL REPRESENTATIVE: Bell, Seltzer, Park & Gibson
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 75 OF 81 USPATFULL
ACCESSION NUMBER: 95:1714 USPATFULL
TITLE: Monoclonal antibodies cross-reactive and cross-protective against P. aeruginosa serotypes
INVENTOR(S): Siadak, Anthony W., Seattle, WA, United States
Rosok, Mae J., Seattle, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5378812		19950103
APPLICATION INFO.:	US 1993-66604		19930524 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1986-931179, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-807391, filed on 10 Dec 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lacey, David L.
ASSISTANT EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Townsend and Townsend Khourie and Crew
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 76 OF 81 USPATFULL
ACCESSION NUMBER: 94:33305 USPATFULL
TITLE: DNA sequence encoding a selectin ligand
INVENTOR(S): Lasky, Laurence A., Sausalito, CA, United States
Imai, Yasuyuki, San Francisco, CA, United States
Rosen, Steven D., San Francisco, CA, United States
Singer, Mark S., Berkeley, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
Regents of the University of California, Alameda, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5304640		19940419
APPLICATION INFO.:	US 1992-834902		19920213 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-695805, filed on 6 May 1991
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartz, Richard A.
ASSISTANT EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 77 OF 81 USPATFULL
ACCESSION NUMBER: 93:54852 USPATFULL
TITLE: Lymphocyte homing receptor/immunoglobulin fusion proteins
INVENTOR(S): Capon, Daniel J., San Mateo, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5225538		19930706
APPLICATION INFO.:	US 1991-808122		19911216 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 78 OF 81 USPATFULL
ACCESSION NUMBER: 92:86949 USPATFULL
TITLE: Serine protease inhibitors
INVENTOR(S): Glover, George I., Creve Coeur, MO, United States
Schasteen, Charles S., University City, MO, United States
PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5157019		19921020
APPLICATION INFO.:	US 1991-728002		19910701 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-200821, filed on 1 Jun 1988, now abandoned which is a continuation of Ser. No. US 1987-6725, filed on 6 Feb 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-840810, filed on 18 Mar 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Y. Christina
LEGAL REPRESENTATIVE: Bennett, Dennis A.
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 79 OF 81 USPATFULL
ACCESSION NUMBER: 92:42890 USPATFULL
TITLE: Hybrid immunoglobulins
INVENTOR(S): Capon, Daniel J., San Mateo, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5116964		19920526
APPLICATION INFO.:	US 1989-440625		19891122 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Lacey, David L.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Dreger, Ginger R., Adler, Carolyn R.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 80 OF 81 USPATFULL
ACCESSION NUMBER: 92:10801 USPATFULL
TITLE: Human monoclonal antibody to lymphadenopathy-associated virus
INVENTOR(S): McClure, Janela, Vashon Island, WA, United States
PATENT ASSIGNEE(S): Genetic Systems Corporation, Redmond, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5087557		19920211
APPLICATION INFO.:	US 1990-498454		19900319 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1986-877579, filed on 23 Jun 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine
LEGAL REPRESENTATIVE: Townsend and Townsend
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 81 OF 81 USPATFULL
ACCESSION NUMBER: 88:2780 USPATFULL
TITLE: Immunomodulating medication based on Fc fragments of human IgG
INVENTOR(S): Carosella, Edgardo D., Lyons, France
Armand, Jacques B., St Germain, France
PATENT ASSIGNEE(S): Institut Merieux, Lyons, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4719107		19880112
APPLICATION INFO.:	US 1984-679445		19841207 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1983-19568	19831207

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

```
  FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH,
     USPATFULL, JAPIO' ENTERED AT 14:47:09 ON 25 OCT 2001
L1          5521 S CONCENTR? AND LYOPHILIZ? AND IMMUNOGLOBULIN?
L2          3813 S L1 AND IGG
L3          3756 S L2 AND PREPAR?
L4           708 S L3 AND (ION EXCHANGE CHROMATOGRAPHY)
L5           706 DUP REM L4 (2 DUPLICATES REMOVED)
L6            24 S L5 AND IGG4

=>
```

L6 ANSWER 1 OF 24 USPATFULL
AN 2001:184842 USPATFULL
TI Fas antigen derivatives
IN Nakamura, Norio, Tokyo, Japan
Nagata, Shigekazu, Osaka-fu, Japan
PA Mochida Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
Osaka Bioscience Institute, Osaka, Japan (non-U.S. corporation)
PI US 6306395 B1 20011023
WO 9742319 19971113
AI US 1998-180100 19981102 (9)
WO 1997-JP1502 19970501
19981102 PCT 371 date
19981102 PCT 102(e) date
PRAI JP 1996-135760 19960502
DT Utility
FS GRANTED
EXNAM Primary Examiner: Huff, Sheela; Assistant Examiner: Harris, Alana M.
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2004
AB This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes Fas antigen derivative, a recombinant DNA molecule which contains DNA sequence, a transformant in which recombinant DNA molecule is introduced, a method for the production of Fas antigen derivative, a medicament which contains novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.

L6 ANSWER 2 OF 24 USPATFULL
AN 2001:165585 USPATFULL
TI Immunoassay technique using multispecific molecules
IN Khaw, Ban-an, Milton, MA, United States
Narula, Jagat, Rosemont, PA, United States
PI US 2001024795 A1 20010927
AI US 2000-727421 A1 20001201 (9)
RLI Continuation-in-part of Ser. No. US 1999-380168, filed on 6 Oct 1999, PENDING
PRAI US 1997-39111 19970226 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for detecting very low **concentrations** of a molecule in a mixture. The detection of the molecule comprises the steps of first contacting a sample with a multispecific molecule capable of binding at least two molecules including the molecule to be detected, wherein the molecule to be detected is bound by the multispecific molecule thereby forming a complex, and second contacting the complex with a second, different molecule which is linked via a polymer to multiple detection signaling molecules. The invention may also be practiced by administration of the multispecific molecule in vivo, to a host for the molecule to be

detected, either with or without the bound polymer probe and thereafter, respectively, either detecting the signaling molecule on the probe, or administering the probe and allowing it to bind the multispecific molecule, followed by detection of the signaling molecule on the probe.

L6 ANSWER 3 OF 24 USPATFULL
AN 2001:160973 USPATFULL
TI Use of heregulin as a growth factor
IN Sliwkowski, Mark X., San Carlos, CA, United States
Kern, Jeffrey A., Iowa City, IA, United States
PI US 2001023241 A1 20010920
AI US 2001-773517 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-243198, filed on 2 Feb 1999, ABANDONED
PRAI US 1998-73866 19980204 (60)
DT Utility
FS APPLICATION
LREP Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 3786
AB Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.

L6 ANSWER 4 OF 24 USPATFULL
AN 2001:142469 USPATFULL
TI Process for producing **immunoglobulins** for intravenous administration and other **immunoglobulin** products
IN Laursen, Inga, Hellerup, Denmark
Teisner, B.o slashed.rge, Odense C, Denmark
PA Statens Serum Institut, Copenhagen S., Denmark (non-U.S. corporation)
PI US 6281336 B1 20010828
AI US 1999-328497 19990609 (9)
PRAI EP 1998-201909 19980609
US 1998-102055 19980928 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saunders, David
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for purifying **immunoglobulin** G from a crude **immunoglobulin** -containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatography are preferably connected in series. An acetate buffer having a pH of about 5.0-6.0 and having a molarity of about 5-25 mM is preferably used throughout the purification process. The invention further comprises an **immunoglobulin** product which is obtainable by this process. The invention also relates to an **immunoglobulin** product which has a purity of more than 98%, has a content of **IgG** monomers and dimers of more than 98.5%, has a content of IgA less than 4 mg of IgA/l, and contains less than 0.5% polymers and aggregates. Said product does not comprise detergent, PEG or albumin as a stabilizer. The product is stable, virus-safe, liquid and ready for instant intravenous administration.

L6 ANSWER 5 OF 24 USPATFULL
AN 2001:141881 USPATFULL
TI Methods of using an AL-1 neurotrophic factor immunoadhesin

IN Caras, Ingrid W., San Francisco, CA, United States
Winslow, John W., El Granada, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6280732 B1 20010828
AI US 1995-486449 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-330128, filed on 27 Oct 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Caputa, Anthony C; Assistant Examiner: Gucker, Stephen
LREP Torchia, Timothy E.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in **preparing** antibodies and in diagnosing and treating various neuronal disorders.

L6 ANSWER 6 OF 24 USPATFULL
AN 2001:59631 USPATFULL
TI Methods for identifying erythropoietin receptor binding protein
IN Middleton, Steven A., Flemington, NJ, United States
Johnson, Dana, Upper Black Eddy, PA, United States
McMahon, Frank J., Whitehouse Station, NJ, United States
Mulkahy, Linda S., Yardley, PA, United States
Jolliffe, Linda K., Belle Mead, NJ, United States
PA Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)
PI US 6221608 B1 20010424
AI US 1997-786690 19970122 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Spector, Lorraine; Assistant Examiner: Kaufman, Claire M.
LREP Wallen, III, John W.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 1671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The extracellular domain of the human erythropoietin receptor (EPO binding protein, EBP) has been expressed and overproduced in E. coli. Control of oxygen levels and pH during high density fermentation allows the production of only the protein variant with the native amino terminus. Methods disclosed permit the efficient recovery of purified EBP which quantitatively binds EPO. The active purified protein competes with membrane associated EPO receptor for binding [.sup.125 I]EPO and neutralizes EPO dependent stimulation in a cell based proliferation assay. Further, the radioligand equilibrium binding constant for this interaction has been determined by immobilizing EBP on agarose gel via a free cysteine. The EBP of the present invention has many uses including the structural determination of the protein by NMR or crystallography, in drug design and discovery, and as a therapeutic. A fusion protein of EBP and an **immunoglobulin** heavy chain was also produced. This protein, termed EBP-Ig, is a preformed dimerization template and is also useful in drug design and discovery methods.

L6 ANSWER 7 OF 24 USPATFULL
AN 2000:167510 USPATFULL
TI Uses of Wnt polypeptides

IN Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
PI US 6159462 20001212
AI US 1997-911860 19970815 (8)
PRAI US 1996-24068 19960816 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Saunders, David; Assistant Examiner: VanderVegt, F. Pierre
LREP Svoboda, Craig G., Carpenter, David A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation, differentiation or maintenance of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.

L6 ANSWER 8 OF 24 USPATFULL
AN 2000:157557 USPATFULL
TI Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
IN Murphy, Gerald P., Seattle, WA, United States
Boynton, Alton L., Redmond, WA, United States
Holmes, Eric H., Bothell, WA, United States
Tino, William Thomas, Redmond, WA, United States
PA Northwest Biotherapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6150508 20001121
AI US 1998-44668 19980318 (9)
RLI Continuation-in-part of Ser. No. US 1997-827017, filed on 25 Mar 1997, now abandoned which is a continuation-in-part of Ser. No. US 1996-621399, filed on 25 Mar 1996, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ungar, Susan
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1,2,7,12
DRWN 24 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.

L6 ANSWER 9 OF 24 USPATFULL
AN 2000:70963 USPATFULL
TI Reshaped monoclonal antibodies against an **immunoglobulin** isotype
IN Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)

PI US 6072035 20000606
AI US 1995-485246 19950607 (8)
RLI Division of Ser. No. US 1993-127721, filed on 27 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Reeves, Julie
LREP Ferraro, Gregory D.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of **immunoglobulin** E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

L6 ANSWER 10 OF 24 USPATFULL
AN 2000:64943 USPATFULL
TI Reshaped monoclonal antibodies against an **immunoglobulin** isotype
IN Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)
PI US 6066718 20000523
AI US 1993-127721 19930927 (8)
RLI Continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Worrall, Timothy A.
LREP Ferrar, Gregory D.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of **immunoglobulin** E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

L6 ANSWER 11 OF 24 USPATFULL
AN 2000:27563 USPATFULL
TI Method for detecting the presence of P-selectin
IN Chesnut, Robert W., Cardiff, CA, United States
Polley, Margaret J., La Jolla, CA, United States
Paulson, James C., Del Mar, CA, United States
Jones, S. Tarran, Radlett, United Kingdom
Saldanha, Jose W., Middlesex, United Kingdom
Bendig, Mary M., London, United Kingdom
Kriegler, Michael, Rancho Santa Fe, CA, United States
Perez, Carl, San Diego, CA, United States
Bayer, Robert, San Diego, CA, United States
Nunn, Michael, San Diego, CA, United States
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6033667 20000307

AI US 1997-964690 19971105 (8)
RLI Continuation of Ser. No. US 1994-202047, filed on 25 Feb 1994, now patented, Pat. No. US 5800815 which is a continuation-in-part of Ser. No. US 1993-57292, filed on 5 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-880196, filed on 5 May 1992, now abandoned
PRAI IL 1993-105614 19930505
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Gambel, Phillip
LREP Campbell & Flores LLP
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 44 Drawing Figure(s); 40 Drawing Page(s)
LN.CNT 4009
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.

L6 ANSWER 12 OF 24 USPATFULL
AN 2000:12616 USPATFULL
TI Chimeric antibodies
IN Hardman, Norman, Riehen, Switzerland
Gill, Laura Lee, Riehen, Switzerland
de Winter, Ronald F. J., Milton Ernest, United Kingdom
Wagner, Kathrin, Basel, Switzerland
Heusser, Christoph, Bottmingen, Switzerland
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 6020153 20000201
AI US 1994-307087 19940916 (8)
RLI Continuation of Ser. No. US 1992-947897, filed on 18 Sep 1992, now abandoned which is a continuation of Ser. No. US 1988-287178, filed on 21 Dec 1988, now abandoned
PRAI GB 1988-77 19880105
GB 1988-20099 19880824
DT Utility
FS Granted
EXNAM Primary Examiner: Ziska, Suzanne E.
LREP Nowak, Henry P., Elmer, James Scott, Foley, Shawn P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the **preparation** of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the **preparation** of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the **preparation** of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.

L6 ANSWER 13 OF 24 USPATFULL

AN 2000:10021 USPATFULL
TI Antibody against human interleukin-5-receptor .alpha. chain
IN Koike, Masamichi, Tokyo, Japan
Furuya, Akiko, Tokyo, Japan
Nakamura, Kazuyasu, Tokyo, Japan
Iida, Akihiro, Tokyo, Japan
Anazawa, Hideharu, Tokyo, Japan
Hanai, Nobuo, Kanagawa, Japan
Takatsu, Kiyoshi, Tokyo, Japan
PA Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 6018032 20000125
WO 9710354 19970320
AI US 1997-836561 19970509 (8)
WO 1996-JP2588 19960911
19970509 PCT 371 date
19970509 PCT 102(e) date
PRAI JP 1995-232384 19950911
DT Utility
FS Granted
EXNAM Primary Examiner: Mertz, Prema
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 61 Drawing Figure(s); 61 Drawing Page(s)
LN.CNT 5703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor .alpha. chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor .alpha. chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

L6 ANSWER 14 OF 24 USPATFULL
AN 1999:136684 USPATFULL
TI Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
IN Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5976534 19991102
AI US 1995-482533 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-366860, filed on 30 Dec 1994, now patented, Pat. No. US 5620687 which is a continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Gambel, Phillip
LREP Parker, Gary E.
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an

anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.

L6 ANSWER 15 OF 24 USPATFULL
AN 1999:117280 USPATFULL
TI Reshaped monoclonal antibodies against an **immunoglobulin** isotype
IN Hardman, Norman, Riehen, Switzerland
Kolbinger, Frank, Freiburg, Germany, Federal Republic of
Saldanha, Jose, Enfield, United Kingdom
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)
PI US 5958708 19990928
AI US 1995-476176 19950607 (8)
RLI Division of Ser. No. US 1993-127721, filed on 27 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-952802, filed on 25 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark
LREP Ferraro, Gregory D.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of **immunoglobulin** E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

L6 ANSWER 16 OF 24 USPATFULL
AN 1998:159916 USPATFULL
TI Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
IN Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5851984 19981222
AI US 1996-696566 19960816 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.; Assistant Examiner: Basham, Daryl A.
LREP Svoboda, Craig G., Marschang, Diane L.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.

L6 ANSWER 17 OF 24 USPATFULL

AN 1998:153858 USPATFULL
TI Antibodies to the antigen campath-1
IN Waldmann, Herman, Cambridge, United Kingdom
Clark, Michael R., Cambridge, United Kingdom
Winter, Gregory P., Cambridge, United Kingdom
Riechmann, Lutz, La Jolla, CA, United States
PA British Technology Group Limited, London, United Kingdom (non-U.S. corporation)
PI US 5846534 19981208
AI US 1994-235705 19940429 (8)
RLI Continuation of Ser. No. US 1993-99480, filed on 30 Jul 1993, now abandoned which is a continuation of Ser. No. US 1992-921601, filed on 3 Aug 1992, now abandoned which is a continuation of Ser. No. US 1989-424233, filed on 12 Oct 1989, now abandoned
PRAI GB 1988-3228 19880212
GB 1988-4464 19880225
DT Utility
FS Granted
EXNAM Primary Examiner: Budens, Robert D.
LREP Nixon & Vanderhye
CLMN Number of Claims: 18
ECL Exemplary Claim: 1,13
DRWN 21 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 1094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.

L6 ANSWER 18 OF 24 USPATFULL
AN 1998:150724 USPATFULL
TI Chimeric antibodies
IN Hardman, Norman, Riehen, Switzerland
Gill, Laura Lee, Riehen, Switzerland
de Winter, Ronald F.J., Milton Ernest, England
Wagner, Kathrin, Basel, Switzerland
Heusser, Christoph, Bottmingen, Switzerland
PA CIBA-GEIGY Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5843708 19981201
AI US 1995-462371 19950605 (8)
RLI Division of Ser. No. US 1994-307087, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1992-947897, filed on 18 Sep 1992, now abandoned which is a continuation of Ser. No. US 1988-287178, filed on 21 Dec 1988, now abandoned
PRAI GB 1988-77 19880105
GB 1988-20099 19880824
DT Utility
FS Granted
EXNAM Primary Examiner: Ziska, Suzanne E.
LREP Nowak, Henry P.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the **preparation** of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the **preparation** of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the **preparation** of said cell lines. The

chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.

L6 ANSWER 19 OF 24 USPATFULL
AN 1998:104391 USPATFULL
TI Antibodies to P-selectin and their uses
IN Chestnut, Robert W., Cardiff, CA, United States
Polley, Margaret J., La Jolla, CA, United States
Paulson, James C., Del Mar, CA, United States
Jones, S. Tarran, Radlett, United Kingdom
Saldanha, Jose W., Middlesex, United Kingdom
Bendig, Mary M., London, United Kingdom
Kriegler, Michael, Rancho Santa Fe, CA, United States
Perez, Carl, San Diego, CA, United States
Bayer, Robert, San Diego, CA, United States
Nunn, Michael, San Diego, CA, United States
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5800815 19980901
AI US 1994-202047 19940225 (8)
RLI Continuation-in-part of Ser. No. US 1993-57292, filed on 5 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-880198, filed on 5 May 1992, now abandoned
PRAI IL 1903-105614 19030505
WO 1993-US4274 19930504
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Gambel, Phillip
LREP Campbell & Flores LLP
CLMN Number of Claims: 57
ECL Exemplary Claim: 32,40
DRWN 47 Drawing Figure(s); 40 Drawing Page(s)
LN.CNT 4013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.

L6 ANSWER 20 OF 24 USPATFULL
AN 1998:82874 USPATFULL
TI Monoclonal antibodies to cytotoxic lymphocyte maturation factor
IN Gately, Maurice Kent, Montville, NJ, United States
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States
Hulmes, Jeffrey David, Ringwood, NJ, United States
Podlaski, Frank John, New City, NY, United States
Stern, Alvin Seth, Passaic Park, NJ, United States
Chizzonite, Richard Anthony, South Kent, CT, United States
Pan, Yu-Ching Eugene, Pine Brook, NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5780597 19980714
AI US 1995-460061 19950602 (8)
RLI Division of Ser. No. US 1994-205011, filed on 2 Mar 1994, now abandoned which is a division of Ser. No. US 1992-857023, filed on 24 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-572284, filed on 27 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-520935, filed on 9 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-455708, filed on 22 Dec 1989, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Cunningham, Thomas M.; Assistant Examiner: Lubet, Martha T.
LREP Johnston, George W., Epstein, William H., Buchholz, Briana C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 44 Drawing Page(s)
LN.CNT 2912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.

L6 ANSWER 21 OF 24 USPATFULL
AN 97:118165 USPATFULL
TI Product and process for targeting an immune response
IN Nemazee, David A., Denver, CO, United States
PA National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)
PI US 5698679 19971216
AI US 1994-309006 19940919 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Eyler, Yvonne
LREP Sheridan Ross P.C.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a product and process for regulating an immune system using an **immunoglobulin** fusion protein capable of targeting a specific peptide precursor to a specific antigen presenting cell. Disclosed is a peptide precursor associated with an **immunoglobulin** molecule capable of binding to an antigen on the surface of an antigen presenting cell. Also disclosed is a nucleic acid molecule having a sequence encoding an **immunoglobulin** fusion protein comprising a peptide precursor and an **immunoglobulin** molecule. The invention is additionally directed to therapeutic reagents which can act as toleragens or immunogens useful in the regulation of an immune response.

L6 ANSWER 22 OF 24 USPATFULL
AN 97:31409 USPATFULL
TI Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
IN Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 5620687 19970415
AI US 1994-366860 19941230 (8)
RLI Continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Gambel, Phillip
LREP Parker, Gary E., Leith, Debra K., Sawislak, Deborah A.
CLMN Number of Claims: 19

ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.

L6 ANSWER 23 OF 24 USPATFULL
AN 97:6049 USPATFULL
TI Method of refolding human IL-13
IN Culpepper, Janice, Mountain View, CA, United States
McKenzie, Andrew, Redwood City, CA, United States
Dang, Warren, San Jose, CA, United States
Zurawski, Gerard, Redwood City, CA, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5596072 19970121
AI US 1993-12543 19930201 (8)
RLI Continuation-in-part of Ser. No. US 1992-933416, filed on 21 Aug 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Spector, Lorraine M.
LREP Ching, Edwin P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 288 Drawing Figure(s); 61 Drawing Page(s)
LN.CNT 4619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids encoding human IL-13, and purified IL-13 proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

L6 ANSWER 24 OF 24 USPATFULL
AN 97:3527 USPATFULL
TI Method of producing an anti-D **immunoglobulin concentrate** and a pharmaceutical **preparation**
IN Hodler, Gerhard, Worb, Switzerland
Lerch, Peter, Bern, Switzerland
Stucki, Martin, Laupen, Switzerland
PA Rotkreuzstiftung Zentrallaboratorium Blutspendedienst, Bern, Switzerland (non-U.S. corporation)
PI US 5593675 19970114
AI US 1994-360334 19941221 (8)
PRAI CH 1993-93810912 19931227
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila
LREP Seed and Berry LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An anti-D **immunoglobulin** G-**preparation** is produced in high-yield from human plasma containing anti-D **IgG**, or a plasma fraction containing an anti-D **IgG**, in which (A) the plasma, or the plasma fraction, with a pH in the range of pH 3.5 to 6.5 and a conductivity value in the range of 2 to 4 mS/cm, is subjected to **ion exchange chromatography** with an adsorbent which has carboxymethyl groups as functional groups, the anti-D **IgG** being bound to the adsorbent, (B) the adsorbent with the bound anti-D **IgG** is first rinsed with a wash solution at a pH in the range of 5 to 8 and a conductivity value in the range of 2 to 4 mS/cm, and the anti-D **IgG** is subsequently eluted, and further (C) the eluted anti-D **IgG** at a pH in the range of 6 to 8 and a conductivity value in the range of 2 to 4 mS/cm is treated with an alkaline adsorbent with ion-exchange characteristics in order to bind undesired components, and finally, the anti-D **IgG** is **concentrated**. The non-infectious anti-D **concentrate** thus obtained possesses a high specific activity of more than 1% anti-D **IgG** per gram of total **IgG**.

=>

```
 s concentr? and lyophiliz? and immunoglobulin?
        196725 CONCENTR?
         60084 CONC
         24730 CONCS
         75545 CONC
                 (CONC OR CONCS)
        133608 CONCD
         12528 CONCG
       1273077 CONCN
        815460 CONCNS
       1794486 CONCN
                 (CONCN OR CONCNS)
       2003854 CONCENTR?
                 (CONCENTR? OR CONC OR CONCD OR CONCG OR CONCN)
         12971 LYOPHILIZ?
         70372 IMMUNOGLOBULIN?
         40048 IG
         11178 IGS
         45106 IG
                 (IG OR IGS)
         88800 IMMUNOGLOBULIN?
                 (IMMUNOGLOBULIN? OR IG)
L7          77 CONCENTR? AND LYOPHILIZ? AND IMMUNOGLOBULIN?

=> d ibib all

L7   ANSWER 1 OF 77  HCAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         2000:683899  HCAPLUS
DOCUMENT NUMBER:          134:67869
TITLE:                    Fibrinolytic serine protease from Spirodela polyrhiza
AUTHOR(S):                Choi, Hye-Seon
CORPORATE SOURCE:         Department of Biological Sciences, University of
                          Ulsan, Ulsan, 680-749, S. Korea
SOURCE:                   KORUS'99, Proc. Russ.-Korean Int. Symp. Sci. Technol.,
                          3rd (1999), Volume 2, 437-440.  Novosibirsk State
                          Technical University: Novosibirsk, Russia.
                          CODEN: 69AKRG
DOCUMENT TYPE:            Conference
LANGUAGE:                 English
AN   2000:683899  HCAPLUS
DN   134:67869
TI   Fibrinolytic serine protease from Spirodela polyrhiza
AU   Choi, Hye-Seon
CS   Department of Biological Sciences, University of Ulsan, Ulsan, 680-749, S.
     Korea
SO   KORUS'99, Proc. Russ.-Korean Int. Symp. Sci. Technol., 3rd (1999), Volume
     2, 437-440 Publisher: Novosibirsk State Technical University, Novosibirsk,
     Russia.
     CODEN: 69AKRG
DT   Conference
LA   English
CC   7-2 (Enzymes)
AB   A serine protease was purified from Chinese herb (Spirodela polyrhiza).
     Protease has a mol. mass of 180,000 dalton and 43,000 dalton in gel
     filtration and SDS-PAGE, resp., implying it is a trimer.  Its optimum pH
     was 4.5-5.0.  Enzyme was stable below 40C.degree. and after
     lyophilization.  The enzyme activity was inhibited significantly
     by leupeptin and to a lesser degree by PMSF.  The protease hydrolyzed not
     only fibrin but also fibrinogen, cleaving A and B without affecting chain
     of fibrinogen.  However, no hydrolysis was found with Hb, Ig,
     and albumin under the same condition.  It cleaved preferentially Arg or
     Lys residue of synthetic substrates (P' position).  The enzyme had an
     anticoagulatory activity measured with activated partial thromboplastin
     time and thrombin time test.  It delayed APTT and TT two times at the
```

protein concn. of 5.0 and 5.7 ug, resp. and drastically reduced after heat treatment.

ST serine proteinase fibrinolysis Spirodela

IT Anticoagulants
(fibrinolytic serine protease from Spirodela polyrhiza)

IT Fibrinogens
Fibrins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(fibrinolytic serine protease from Spirodela polyrhiza)

IT 37259-58-8P, Serine proteinase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)
(fibrinolytic serine protease from Spirodela polyrhiza)

IT 9002-04-4, Thrombin 65316-83-8 69861-90-1 73392-19-5
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(fibrinolytic serine protease from Spirodela polyrhiza)

RE.CNT 9

RE

(1) Choi, H; Mycologia 1998, V90, P674 HCAPLUS
(2) Hollman, W; J Biol Chem 1976, V251, P1663
(3) Jeon, O; Kor J Biochem 1995, V28, P138 HCAPLUS
(4) Naski, M; J Biol Chem 1990, V265, P13484 HCAPLUS
(5) Nikai, T; Arch Biochem Biophys 1984, V231, P309 HCAPLUS
(6) Noeske-Jungblut, C; J Biol Chem 1995, V270, P28629 HCAPLUS
(7) Olson, S; J Biol Chem 1992, V267, P12528 HCAPLUS
(8) Shin, H; J Microbiol 1998, V36, P20 HCAPLUS
(9) Strube, K; J Biol Chem 1993, V268, P8590 HCAPLUS

=> d 2-77

L7 ANSWER 2 OF 77 HCAPLUS COPYRIGHT 2001 ACS

AN 2000:592533 HCAPLUS

DN 133:198650

TI Biodegradable composite material for the production of microcapsules

IN Teller, Marianne; Heinrich, Hans-Werner; Teller, Joachim; Meyer, Udo

PA Bioserv A.-G., Germany

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048573	A1	20000824	WO 2000-DE526	20000220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10008880	A1	20000824	DE 2000-10008880	20000220

PRAI DE 1999-19907227 19990219

RE.CNT 6

RE

(1) Narayan, R; US 5540929 A 1996 HCAPLUS
(2) Poly Med Inc; EP 0737703 A 1996 HCAPLUS
(3) Syntex Inc; EP 0052510 A 1982 HCAPLUS
(4) Syntex Inc; EP 0251476 A 1988 HCAPLUS
(5) Takeda Chemical Industries Ltd; EP 0601799 A 1994 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:149842 HCAPLUS
DN 132:150931
TI Manufacture of milk power with specific immune globulin
IN Wang, Wenrong
PA Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 5 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1173288	A	19980218	CN 1997-115852	19970828
	CN 1059128	B	20001206		

L7 ANSWER 4 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:65297 HCAPLUS
DN 132:113093
TI Compositions containing lysin enzyme for prevention and treatment of group A streptococcal infections
IN Fischetti, Vincent; Loomis, Lawrence
PA New Horizons Diagnostics, USA
SO U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 962,523.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6017528	A	20000125	US 1999-257025	19990225
	US 5997862	A	19991207	US 1997-962523	19971031
	WO 2000050069	A1	20000831	WO 1999-US4063	19990225
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9928767	A1	20000914	AU 1999-28767	19990225
PRAI	US 1997-962523	19971031			
	US 1999-257025	19990225			
	WO 1999-US4063	19990225			

L7 ANSWER 5 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:732954 HCAPLUS
DN 131:356096
TI Oral delivery system containing a group C streptococcal phage-associated lysin enzyme for prophylactic and therapeutic treatment of group A streptococcal infection
IN Fischetti, Vincent; Loomis, Lawrence
PA New Horizons Diagnostics Corp., USA
SO U.S., 5 pp., Division of U.S. Ser. No. 962,523.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 5985271 A 19991116 US 1999-257026 19990225
US 5997862 A 19991207 US 1997-962523 19971031
AU 9928767 A1 20000914 AU 1999-28767 19990225
PRAI US 1997-962523 19971031
WO 1999-US4063 19990225
RE.CNT 2
RE
(1) Fischetti; US 5604109 1997 HCAPLUS
(2) Scott; US 4784948 1988 HCAPLUS

L7 ANSWER 6 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:182963 HCAPLUS
DN 130:219694
TI A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders
AU Bos, R.; Laterveer-Vreeswijk, G. H.; Lockwood, D.; Szewczyk, K.; Nieuwenhuizen, W.
CS Gaubius Laboratory, TNO Prevention Health, Leiden, 2333 CA, Neth.
SO Thromb. Haemostasis (1999), 81(1), 54-59
CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal
LA English
RE.CNT 30
RE
(3) Bos, R; Eur J Clin Inv 1997, V27, P148 HCAPLUS
(5) Carville, D; Clin Chem 1996, V42, P1537 HCAPLUS
(6) Dempfle, C; Thromb Haemost 1995, V74, P673 HCAPLUS
(8) Emeis, J; Fibrinolysis & Proteolysis 1997, V11, P67 HCAPLUS
(10) Ginsberg, J; Thromb Haemost 1995, V74, P833 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:172617 HCAPLUS
DN 130:213644
TI Dried biologically or therapeutically active preparations
IN Kanellos, Jerry; Oates, Adrian; Goss, Neil
PA CSL Limited, Australia
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9910011	A1	19990304	WO 1998-AU682	19980825
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9807633	A	19990225	ZA 1998-7633	19980824
AU 9887231	A1	19990316	AU 1998-87231	19980825
EP 1009438	A1	20000621	EP 1998-938550	19980825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI AU 1997-8719 19970825
WO 1998-AU682 19980825
RE.CNT 10
RE
(1) Asahi Chem Ind Co Ltd; JP 05331071 A 1993 HCAPLUS

(2) Asahi Chem Ind Co Ltd; JP 06321805 A 1994 HCAPLUS
(3) Behringwerke Aktiengesellschaft; US 4297344 A 1981 HCAPLUS
(4) Behringwerke Aktiengesellshaft; US 4562072 A 1985 HCAPLUS
(5) Miles Laboratories Inc; US 4623717 A 1986 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:265356 HCAPLUS
TI Comparison of freezing and **lyophilizing** for preservation of colostrum as a source of **immunoglobulins** for calves
AU Klobasa, F.; Goel, M. C.; Werhahn, E.
CS Institute of Animal Husbandry and Animal Ethology, Mariensee, Germany
SO J. Anim. Sci. (1998), 76(4), 923-926
CODEN: JANSAG; ISSN: 0021-8812
PB American Society of Animal Science
DT Journal
LA English

L7 ANSWER 9 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:145737 HCAPLUS
DN 128:269347
TI Protein G affinity chromatography as a method for isolating **immunoglobulins** for the treatment of immunodeficiency in marine mammals
AU Schwertner, Harvey A.; Dalton, Leslie M.; Mcbain, James F.; Patterson, Wayne R.
CS Clinical Investigation Directorate, Wilford Hall Medical Center/RDL, Lackland AFB, TX, 78236-5319, USA
SO Int. J. Bio-Chromatogr. (1997), 3(3), 207-214
CODEN: IJOBEQ; ISSN: 1068-0659
PB Harwood Academic Publishers
DT Journal
LA English

L7 ANSWER 10 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:864497 HCAPLUS
DN 123:278459
TI Antibodies as therapeutic agents: the antivenoms
AU Dart, Richard C.
CS Rocky Mountain Poison Center, Denver, CO, 80204, USA
SO J. Nat. Toxins (1995), Volume Date 1995, 4(2), 155-63
CODEN: JNTOER; ISSN: 1058-8108
DT Journal
LA English

L7 ANSWER 11 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:794883 HCAPLUS
DN 123:179357
TI Preparation of **concentrated immunoglobulins** G for therapeutic uses
IN Burnouf, Miryana; Dernis, Dominique; Bonneel, Patrick; Burnouf, Thierry
PA Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord, Fr.
SO Fr. Demande, 13 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2706466	A1	19941223	FR 1993-7128	19930614
	FR 2706466	B1	19950825		
	CA 2165203	AA	19941222	CA 1994-2165203	19940613
	WO 9429334	A1	19941222	WO 1994-FR699	19940613

W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9470023	A1	19950103	AU 1994-70023	19940613
	EP 703922	A1	19960403	EP 1994-918916	19940613
	EP 703922	B1	20000517		
	R: AT, BE, CH, DE, DK, ES, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09500369	T2	19970114	JP 1994-501424	19940613
	BR 9406814	A	20000530	BR 1994-6814	19940613
	AT 193020	E	20000615	AT 1994-918916	19940613
	ES 2148332	T3	20001016	ES 1994-918916	19940613
	US 6069236	A	20000530	US 1996-564030	19960325
PRAI	FR 1993-7128	19930614			
	WO 1994-FR699	19940613			

L7 ANSWER 12 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:761725 HCAPLUS
DN 123:152869
TI Highly **concentrated immunoglobulin** composition and method to prepare it
IN Eibl, Johann; Linnau, Yendra; Teschner, Wolfgang
PA Immuno A.-G., Austria
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 661060	A2	19950705	EP 1994-120595	19941223
	EP 661060	A3	19970115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, SE				
	DE 4344824	C1	19950831	DE 1993-4344824	19931228
	US 5608038	A	19970304	US 1994-359901	19941220
	AT 9402378	A	20001015	AT 1994-2378	19941221
	CA 2138853	AA	19950629	CA 1994-2138853	19941222
	CZ 284186	B6	19980916	CZ 1994-3284	19941222
	FI 9406104	A	19950629	FI 1994-6104	19941227
	NO 9405045	A	19950629	NO 1994-5045	19941227
	JP 07206709	A2	19950808	JP 1994-325623	19941227
	JP 3040678	B2	20000515		
	HU 70449	A2	19951030	HU 1994-3795	19941227
	RU 2104713	C1	19980220	RU 1994-45287	19941227
PRAI	DE 1993-4344824	19931228			

L7 ANSWER 13 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:760971 HCAPLUS
DN 123:297795
TI Aggregation of IgG on methylated silicon surfaces studied by tapping mode atomic force microscopy
AU Waelivaara, Bengt; Warkentin, Peter; Lundstroem, Ingemar; Tengvall, Pentti
CS Lab. Appl. Phys., Linkoeping Univ. IFM, Linkoeping, S-578183, Swed.
SO J. Colloid Interface Sci. (1995), 174(1), 53-60
CODEN: JCISA5; ISSN: 0021-9797
DT Journal
LA English

L7 ANSWER 14 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:89045 HCAPLUS
DN 122:30119
TI Stability of membrane-sterilized bovine **immunoglobulin** aseptically added to UHT milk

AU Fukumoto, L. R.; Skura, B. J.; Nakai, S.
CS Dep. Food Sci., Univ. British Columbia, Vancouver, BC, V6T 1Z4, Can.
SO J. Food Sci. (1994), 59(4), 757-9, 762
CODEN: JFDSAZ; ISSN: 0022-1147
DT Journal
LA English

L7 ANSWER 15 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:692443 HCAPLUS
DN 121:292443
TI Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines
AU Buts, Jean-Paul; Keyser, Nadine De; Raedemaeker, Laurence De
CS Faculty Medicine, Catholic University Louvain, Brussels, Belg.
SO Pediatr. Res. (1994), 36(4), 522-7
CODEN: PEREBL; ISSN: 0031-3998
DT Journal
LA English

L7 ANSWER 16 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:537073 HCAPLUS
DN 119:137073
TI Serum **immunoglobulin concentrations** after feeding maternal colostrum or maternal colostrum plus colostral supplement to dairy calves
AU Francisco, S. F. Abel; Quigley, J. D., III
CS Inst. Agric., Univ. Tennessee, Knoxville, TN, 37901-1071, USA
SO Am. J. Vet. Res. (1993), 54(7), 1051-4
CODEN: AJVRAH; ISSN: 0002-9645
DT Journal
LA English

L7 ANSWER 17 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:465043 HCAPLUS
DN 119:65043
TI Enzyme immunoassay system for the determination of haprin in the air
AU Kaplunova, O. P.; Apanovich, I. A.; Dikareva, T. V.; Apenova, N. N.
CS NII Biol. Priborostr., Moscow, Russia
SO Zh. Mikrobiol., Epidemiol. Immunobiol. (1992), (9-10), 60-3
CODEN: ZMEIAV; ISSN: 0372-9311
DT Journal
LA Russian

L7 ANSWER 18 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:407227 HCAPLUS
DN 119:7227
TI Preparation of stable anti-rabies **immunoglobulins**
IN Fedorovskaya, Elena A.; Rybalskaya, Alla P.; Selimov, Midat A.; Sobolev, Vladimir F.; Shinkarenko, Anna A.; Logvinova, Valentina P.
PA Ki nii gematologii perelivaniya krovi, USSR
SO U.S.S.R.
From: Izobreteniya 1992, (25), 18.
CODEN: URXXAF
DT Patent
LA Russian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1745257	A1	19920707	SU 1990-4852152	19900718

L7 ANSWER 19 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:45553 HCAPLUS
DN 118:45553
TI Manufacture and in vitro characterization of a solvent/detergent-treated

human plasma
AU Hellstern, Peter; Sachse, Hans; Schwinn, Horst; Oberfrank, Klaus
CS Inst. Transfusionsmed. Immunhaematol., Klin. Ludwigshafen, Ludwigshafen, W-6700, Germany
SO Vox Sang. (1992), 63(3), 178-85
CODEN: VOSAAD; ISSN: 0042-9007
DT Journal
LA English

L7 ANSWER 20 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:605324 HCAPLUS
DN 117:205324
TI Isolation of human thyrotropin in one step using activated polystyrene beads for immunoaffinity adsorption
AU Survilo, L. I.; Budnikova, L. P.; Karpova, T. V.; Sviridov, O. V.
CS Inst. Bioorg. Chem., Minsk, 220067, Belarus
SO Biotekhnologiya (1992), (3), 32-4
CODEN: BTKNEZ; ISSN: 0234-2758
DT Journal
LA Russian

L7 ANSWER 21 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:476541 HCAPLUS
DN 117:76541
TI Preparation of **immunoglobulins** for intramuscular injection
IN Stepanek, Ivan
PA Czech.
SO Czech., 4 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 272716	B1	19910212	CS 1987-7098	19871002

L7 ANSWER 22 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:554532 HCAPLUS
DN 115:154532
TI Direct radiolabeling of antibodies and other proteins with technetium or rhenium using tin disulfide bond reducing agent pretreatment
IN Rhodes, Buck A.
PA USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9101754	A1	19910221	WO 1990-US4461	19900808
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	US 5078985	A	19920107	US 1989-391474	19890809
	CA 2065299	AA	19910210	CA 1990-2065299	19900808
	AU 9065434	A1	19910311	AU 1990-65434	19900808
	AU 650629	B2	19940630		
	EP 486622	A1	19920527	EP 1990-915377	19900808
	EP 486622	B1	19981104		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 05508699	T2	19931202	JP 1990-514313	19900808
	JP 3070763	B2	20000731		
	AT 172879	E	19981115	AT 1990-915377	19900808
	ES 2125854	T3	19990316	ES 1990-915377	19900808

	JP 2000053590	A2	20000222	JP 1999-227755	19900808
	US 35457	E	19970218	US 1995-389267	19950216
PRAI	US 1989-391474	19890809			
	JP 1990-514313	19900808			
	US 1990-565275	19900808			
	WO 1990-US4461	19900808			

L7 ANSWER 23 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:542328 HCAPLUS
DN 115:142328
TI Formulation of intramuscular injections of IgG, IgM, and IgA
IN Stepanek, Ivan
PA Czech.
SO Czech., 7 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 266252	B1	19891213	CS 1984-7200	19840925

L7 ANSWER 24 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:227377 HCAPLUS
DN 114:227377
TI Process for preparing an **immunoglobulin** preparation from colostrum
IN Stephan, Wolfgang; Dichtelmueller, Herbert
PA Biotest Pharma G.m.b.H., Fed. Rep. Ger.
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410272	A1	19910130	EP 1990-113651	19900717
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 3924420	A1	19910131	DE 1989-3924420	19890724
PRAI	DE 1989-3924420	19890724			

L7 ANSWER 25 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:628694 HCAPLUS
DN 113:228694
TI Characterization of new human pancreatic cancer cell lines which propagate in a protein-free chemically defined medium
AU Yamaguchi, Nozomi; Yamamura, Yoshiro; Koyama, Kunihiko; Ohtsuji, Eigo; Imanishi, Jiro; Ashihara, Tsukasa
CS Dep. Microbiol., Kyoto Prefect. Univ. Med., Kyoto, 602, Japan
SO Cancer Res. (1990), 50(21), 7008-14
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L7 ANSWER 26 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:484819 HCAPLUS
DN 113:84819
TI Therapeutic IgM **concentrates**
IN Collins, Michael S.; Opitz, Hans Georg; Lundblad, John L.; Seng, Richard L.
PA Miles, Inc., USA
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 345543	A2	19891213	EP 1989-109372	19890524
	EP 345543	A3	19900613		
	EP 345543	B1	19941012		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 90281	A1	19941007	IL 1989-90281	19890512
	ES 2060695	T3	19941201	ES 1989-109372	19890524
	DK 8902703	A	19891207	DK 1989-2703	19890602
	JP 02067228	A2	19900307	JP 1989-141278	19890605
	JP 2703341	B2	19980126		
PRAI	US 1988-203377	19880606			

L7 ANSWER 27 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:639479 HCAPLUS
DN 111:239479
TI Preparation of cytokine conjugates with human **Ig** and pharmaceuticals containing them
IN Von Wussow, Peter
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 305967	A2	19890308	EP 1988-114130	19880830
	EP 305967	A3	19900131		
	EP 305967	B1	19930505		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 88900	E	19930515	AT 1988-114130	19880830
	ES 2054753	T3	19940816	ES 1988-114130	19880830
	FI 8804013	A	19890303	FI 1988-4013	19880831
	ZA 8806471	A	19890426	ZA 1988-6471	19880831
	DK 8804865	A	19890303	DK 1988-4865	19880901
	NO 8803896	A	19890303	NO 1988-3896	19880901
	AU 8821725	A1	19890323	AU 1988-21725	19880901
	AU 627694	B2	19920903		
	JP 01090200	A2	19890406	JP 1988-216441	19880901
PRAI	CH 1987-3357	19870902			
	EP 1988-114130	19880830			

L7 ANSWER 28 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:639469 HCAPLUS
DN 111:239469
TI Purification and stabilization of **immunoglobulin** M antibodies
IN Dove, George; Mitra, Gautam
PA Miles, Inc., USA
SO Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 303088	A2	19890215	EP 1988-111931	19880725
	EP 303088	A3	19890517		
	EP 303088	B1	19921111		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 82136	E	19921115	AT 1988-111931	19880725
	ES 2045027	T3	19940116	ES 1988-111931	19880725

	AU 8820315	A1	19890608	AU 1988-20315	19880802
	AU 618745	B2	19920109		
	JP 02000493	A2	19900105	JP 1988-197281	19880809
	JP 2730913	B2	19980325		
	US 5157113	A	19921020	US 1991-684415	19910412
PRAI	US 1987-83136	19870810			
	EP 1988-111931	19880725			

L7 ANSWER 29 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:628420 HCAPLUS
DN 111:228420
TI Evaluation of an albumin **concentration** method using ultrafiltration
AU Geschier, C.; Streiff, F.; Stoltz, J. F.
CS Cent. Reg. Transfus. Sanguine, Vandoeuvre-les-Nancy, 51511, Fr.
SO Colloq. INSERM (1989), 175(Biotechnol. Proteines Plasma), 33-41
CODEN: CINMDE; ISSN: 0768-3154
DT Journal
LA English

L7 ANSWER 30 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:502683 HCAPLUS
DN 111:102683
TI Method for the preparation of **immunoglobulins** suitable for intravenous administration
IN Gazzei, Guido; Giannozzi, Aldo; Valeri, Andrea
PA Sclavo S.p.A., Italy
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 221505	A2	19870513	EP 1986-115016	19861029
	EP 221505	A3	19880504		
	EP 221505	B1	19910814		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 8664278	A1	19870514	AU 1986-64278	19861022
	CA 1306964	A1	19920901	CA 1986-521255	19861023
	AT 66151	E	19910815	AT 1986-115016	19861029
	ES 2033231	T3	19930316	ES 1986-115016	19861029
	ZA 8608271	A	19870624	ZA 1986-8271	19861030
	JP 62114919	A2	19870526	JP 1986-264125	19861107
PRAI	IT 1985-22766	19851108			
	EP 1986-115016	19861029			

L7 ANSWER 31 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:199175 HCAPLUS
DN 110:199175
TI Method of preparing **immunoglobulins** against human lymphocytes
IN Hamsikova, Eva; Pardon, Jan; Ulrych, Stanislav
PA Czech.
SO Czech., 5 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 247484	B1	19870115	CS 1985-2724	19850412

L7 ANSWER 32 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:150957 HCAPLUS

DN 110:150957
TI Isolation of albumin-containing proteins from human plasma with hydrogen peroxide and caprylic acid
IN Bulik, Jozef; Banda, Imrich; Stachy, Alfred
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 248241	B1	19870212	CS 1985-5958	19850816

L7 ANSWER 33 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:101761 HCAPLUS
DN 110:101761
TI Stable formulations of ricin toxin A chain and of its immunoconjugates and stabilizer screening methods therefor
IN Ferris, Robert
PA Cetus Corp., USA
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 271918	A2	19880622	EP 1987-118817	19871218
EP 271918	A3	19891213		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4808705	A	19890228	US 1986-944347	19861219
CA 1305417	A1	19920721	CA 1987-553125	19871130
NO 8705232	A	19880620	NO 1987-5232	19871215
DK 8706705	A	19880620	DK 1987-6705	19871218
FI 8705608	A	19880620	FI 1987-5608	19871218
AU 8782801	A1	19880623	AU 1987-82801	19871218
AU 593489	B2	19900208		
HU 45401	A2	19880728	HU 1987-5867	19871218
JP 63258426	A2	19881025	JP 1987-320158	19871219
PRAI US 1986-944347		19861219		

L7 ANSWER 34 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:637006 HCAPLUS
DN 109:237006
TI Method for preparing a mixture of **immunoglobulins** and histamine
IN Stachy, Alfred; Bulik, Josef; Banda, Imrich
PA Czech.
SO Czech., 2 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 244957	B1	19860814	CS 1983-8610	19831121

L7 ANSWER 35 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:616033 HCAPLUS
DN 109:216033
TI **Immunoglobulin**- and transferrin-containing intravenous or intraperitoneal injections for control of gram-negative bacterial infections
IN Stachy, Alfred; Lucansky, Anton; Bulik, Jozef; Banda, Imrich

PA Czech.
SO Czech., 2 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 248954	B1	19870312	CS 1983-921	19830210

L7 ANSWER 36 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:498815 HCAPLUS
DN 109:98815
TI Method of producing virus- and blood group substance-free **immunoglobulin** preparations for intravenous injection
IN Uemura, Yahiro; Uriyu, Katsuhiro; Takechi, Kazuo; Hirao, Yutaka; Suyama, Tadakazu
PA Green Cross Corp., Japan
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 246579	A2	19871125	EP 1987-107112	19870516
	EP 246579	A3	19890517		
	EP 246579	B1	19930804		
	R: CH, DE, ES, FR, GB, LI				
	JP 63183539	A2	19880728	JP 1987-21481	19870131
	JP 06062436	B4	19940817		
	JP 09176045	A2	19970708	JP 1996-245419	19870131
	ES 2042519	T3	19931216	ES 1987-107112	19870516
	JP 63045229	A2	19880226	JP 1987-204824	19870818
	US 5132406	A	19920721	US 1989-348139	19890505
PRAI	JP 1986-114421	19860519			
	JP 1986-234757	19860930			
	JP 1987-21481	19870131			
	JP 1987-204824	19870131			
	US 1987-52370	19870519			

L7 ANSWER 37 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:479751 HCAPLUS
DN 109:79751
TI ~~Process for the preparation of lyophilized and heat-treated blood coagulation factor VIII~~
IN Schwarz, Otto; Linnau, Yendra
PA Immuno A.-G. fuer Chemisch-Medizinische Produkte, Austria
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 270516	A2	19880608	EP 1987-890237	19871029
	EP 270516	A3	19880622		
	EP 270516	B1	19910403		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	AT 8602923	A	19900615	AT 1986-2923	19861103
	AT 391808	B	19901210		
	US 4814435	A	19890321	US 1987-108458	19871015
	CA 1297011	A1	19920310	CA 1987-549552	19871019
	AT 62133	E	19910415	AT 1987-890237	19871029

	ES 2028913	T3	19920716	ES 1987-890237	19871029
	DK 8705735	A	19880504	DK 1987-5735	19871102
	JP 63132899	A2	19880604	JP 1987-278985	19871102
	JP 07030117	B4	19950405		
PRAI	AT 1986-2923	19861103			
	EP 1987-890237	19871029			

L7 ANSWER 38 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:421322 HCAPLUS
DN 109:21322
TI Protection by milk **immunoglobulin concentrate** against oral challenge with enterotoxigenic Escherichia coli
AU Tacket, Carol O.; Losonsky, Genevieve; Link, Harriet; Hoang, Yen; Guesry, Pierre; Hilpert, Helmut; Levine, Myron M.
CS Sch. Med., Univ. Maryland, Baltimore, MD, USA
SO N. Engl. J. Med. (1988), 318(19), 1240-3
CODEN: NEJMAG; ISSN: 0028-4793
DT Journal
LA English

L7 ANSWER 39 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:173524 HCAPLUS
DN 108:173524
TI Antibacterial albumin-**immunoglobulin** intravenous composition
IN Stachy, Alfred; Bulik, Jozef; Banda, Imrich
PA Czech.
SO Czech., 2 pp.
CODEN: CZXXA9
DT Patent
LA Slovak
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 237866	B1	19851113	CS 1983-533	19830127

L7 ANSWER 40 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:165844 HCAPLUS
DN 108:165844
TI Kinetics of classes of antibodies to Capillaria hepatica using indirect fluorescent antibody test during murine infection
AU Lee, Suk Hwan; Eom, Kee Seon; Rim, Han Jong
CS Coll. Med., Korea Univ., Seoul, S. Korea
SO Koryo Taehakkyo Uikwa Taehak Nonmunjip (1987), 24(3), 97-105
CODEN: KTUNDD
DT Journal
LA Korean

L7 ANSWER 41 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1988:156308 HCAPLUS
DN 108:156308
TI Effect of virucidal heat treatment on proteins in human factor VIII **concentrates**
AU Thomas, Kathrin B.; McGrath, Katherine M.; Taylor, Michael; Young, Ian F.; Herrington, Robert W.; Schiff, Peter
CS Red Cross Blood Bank, South Melbourne, 3205, Australia
SO Transfusion (Philadelphia) (1988), 28(1), 8-13
CODEN: TRANAT; ISSN: 0041-1132
DT Journal
LA English

L7 ANSWER 42 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1987:144001 HCAPLUS
DN 106:144001
TI Extraction of milk proteins and manufacture of pharmaceutical products

IN Monsan, Pierre Frodoric Emmanuel; Thibault, Philippe Andro; Brossard, Claudine; Bruvier, Chritine Solange Jeanne
PA Roussel-UCLAF , Fr.
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3623474	A1	19870115	DE 1986-3623474	19860711
	DE 3623474	C2	19950921		
	FR 2584727	A1	19870116	FR 1985-10649	19850711
	FR 2584727	B1	19880617		
	SE 8602877	A	19870112	SE 1986-2877	19860627
	BE 905087	A1	19870112	BE 1986-216905	19860710
	DK 8603273	A	19870112	DK 1986-3273	19860710
	NL 8601814	A	19870202	NL 1986-1814	19860710
	GB 2179947	A1	19870318	GB 1986-16819	19860710
	GB 2179947	B2	19890712		
	CH 668428	A	19881230	CH 1986-2771	19860710
	JP 62019523	A2	19870128	JP 1986-162200	19860711
PRAI	FR 1985-10649		19850711		

L7 ANSWER 43 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1986:184471 HCAPLUS
DN 104:184471
TI Use of microbore high-performance liquid chromatography for purifying subnanomole levels of polypeptides for microsequencing. Structural studies on the murine plasma cell antigen PC-1
AU Grego, Boris; Van Driel, Ian R.; Goding, James W.; Nice, Edouard C.; Simpson, Richard J.
CS Jt. Protein Struct. Lab., Ludwig Inst. Cancer Res., Parkville, Australia
SO Int. J. Pept. Protein Res. (1986), 27(2), 201-7
CODEN: IJPPC3; ISSN: 0367-8377
DT Journal
LA English

L7 ANSWER 44 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1986:184450 HCAPLUS
DN 104:184450
TI Preservation of erythrocytic **immunoglobulin** diagnostic agents
AU Shmuter, M. F.; Mukatova, G. D.; Tleugabylova, A. M.; Aimanova, O. Ya.; Menshov, P. I.
CS Sredneaziat. Nauchno-Issled. Protivochumnyi Inst., Alma-Ata, USSR
SO Lab. Delo (1986), (3), 170-2
CODEN: LABDAZ; ISSN: 0023-6748
DT Journal
LA Russian

L7 ANSWER 45 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1985:459288 HCAPLUS
DN 103:59288
TI Inactivating pathogens in blood plasma products.
IN Philapitsch, Anton; Woeber, Guenter; Eibl, Johann; Schwarz, Otto
PA Immuno A.-G. fuer Chemische-Medizinische Produkte, Austria
SO Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 124506	A2	19841107	EP 1984-890074	19840426

	EP 124506	A3	19850703			
	EP 124506	B1	19880817			
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE					
	AT 8301593	A	19840615	AT 1983-1593	19830502	
	AT 376884	B	19850110			
	AT 8301592	A	19840615	AT 1983-1592	19830502	
	AT 376883	B	19850110			
	AT 8301591	A	19840615	AT 1983-1591	19830502	
	AT 376882	B	19850110			
	AT 8301590	A	19840615	AT 1983-1590	19830502	
	AT 376881	B	19850110			
	AT 36457	E	19880915	AT 1984-890074	19840426	
	ES 532075	A1	19850616	ES 1984-532075	19840430	
	US 4687664	A	19870818	US 1984-605658	19840430	
	JP 59206314	A2	19841122	JP 1984-89173	19840502	
	JP 05085524	B4	19931207			
PRAI	AT 1983-1590	19830502				
	AT 1983-1591	19830502				
	AT 1983-1592	19830502				
	AT 1983-1593	19830502				
	EP 1984-890074	19840426				

L7 ANSWER 46 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1985:119611 HCAPLUS
DN 102:119611
TI Plasma fraction containing Factor VIII (AHF)
IN Linnau, Yendra; Schwarz, Otto
PA Immuno A.-G. fuer Chemisch-Medizinische Produkte, Austria
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 127603	A2	19841205	EP 1984-890083	19840510
	EP 127603	A3	19860903		
	EP 127603	B1	19890104		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 8301858	A	19850615	AT 1983-1858	19830520
	AT 379510	B	19860127		
	AT 39618	E	19890115	AT 1984-890083	19840510
	DK 8402415	A	19841121	DK 1984-2415	19840516
	DK 158281	B	19900430		
	DK 158281	C	19901001		
	CA 1225331	A1	19870811	CA 1984-454413	19840516
	US 4522751	A	19850611	US 1984-611638	19840518
	ES 532640	A1	19850616	ES 1984-532640	19840518
	JP 59222420	A2	19841214	JP 1984-101636	19840519
	JP 05053777	B4	19930810		
PRAI	AT 1983-1858	19830520			
	EP 1984-890083	19840510			

L7 ANSWER 47 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:607139 HCAPLUS
DN 101:207139
TI A comparison of three different methods of **concentration** of urinary proteins
AU Ala-Houhala, Ilpo; Parviainen, Markku T.; Pasternack, Amos
CS Dep. Clin. Sci., Univ. Tampere, Tampere, Finland
SO Clin. Chim. Acta (1984), 142(3), 339-42
CODEN: CCATAR; ISSN: 0009-8981
DT Journal
LA English

L7 ANSWER 48 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:497627 HCAPLUS
DN 101:97627
TI Specfic anti-Rho(D) human gamma-globulin
IN Kendi, Vanghel; Balan, Stefan
PA Centrul de Hematologie, Rom.
SO Rom., 3 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RO 77686	B	19811124	RO 1980-99839	19800111

L7 ANSWER 49 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:412196 HCAPLUS
DN 101:12196
TI Gamma globulin-containing compositions
IN Hooper, John A.; Mankarious, Samia; Liu-Rash, Catherine R.
PA Baxter Travenol Laboratories, Inc., USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8400891	A1	19840315	WO 1983-US1016	19830701
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, SE				
	EP 116571	A1	19840829	EP 1983-902407	19830701
	EP 116571	B1	19910828		
	EP 116571	B2	19971029		
	R: AT, BE, CH, DE, FR, GB, LI, SE				
	JP 59501546	T2	19840830	JP 1983-502448	19830701
	JP 08000787	B4	19960110		
	AT 66616	E	19910915	AT 1983-902407	19830701
	CA 1239584	A1	19880726	CA 1983-433121	19830725
	ES 524890	A1	19860201	ES 1983-524890	19830811
PRAI	US 1982-413059	19820830			
	EP 1983-902407	19830701			
	WO 1983-US1016	19830701			

L7 ANSWER 50 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:215500 HCAPLUS
DN 100:215500
TI Stabilized gamma-globulin **concentrate**
IN Hooper, John A.; Mankarious, Samia; Liu-Rash, Catherine R.
PA Baxter Travenol Laboratories, Inc., USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8400890	A1	19840315	WO 1983-US1015	19830630
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, SE				
	US 4439421	A	19840327	US 1982-413060	19820830
	JP 59501547	T2	19840830	JP 1983-502452	19830630
	JP 07116058	B4	19951213		

	EP 118462	A1	19840919	EP 1983-902406	19830630
	EP 118462	B1	19910925		
	R: AT, BE, CH, DE, FR, GB, LI, SE				
	AT 67670	E	19911015	AT 1983-902406	19830630
	CA 1219211	A1	19870317	CA 1983-432209	19830711
	ES 525246	A1	19850901	ES 1983-525246	19830830
	CA 1231895	A2	19880126	CA 1986-521282	19861023
PRAI	US 1982-413060	19820830			
	EP 1983-902406	19830630			
	WO 1983-US1015	19830630			
	CA 1983-432209	19830711			

L7 ANSWER 51 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:115102 HCAPLUS
DN 100:115102
TI Stability problems with urease-steroid conjugates
AU Samake, H.; Rajkowski, K. M.; Cittanova, N.
CS UER Biomed. Saints-Peres, Univ. Paris-V, Paris, F-75006, Fr.
SO Dev. Immunol. (1983), 18(Immunoenzym. Tech.), 175-8
CODEN: DEIMD6; ISSN: 0163-5921
DT Journal
LA English

L7 ANSWER 52 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1984:21407 HCAPLUS
DN 100:21407
TI T cell-replacing factor for glucocorticosteroid-induced **immunoglobulin** production. A unique steroid-dependent cytokine
AU Orson, Frank M.; Grayson, Jane; Pike, Sandra; De Seau, Virginia; Blaese, R. Michael
CS Metab. Branch, Natl. Cancer Inst., Bethesda, MD, 20205, USA
SO J. Exp. Med. (1983), 158(5), 1473-82
CODEN: JEMEAV; ISSN: 0022-1007
DT Journal
LA English

L7 ANSWER 53 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1983:546103 HCAPLUS
DN 99:146103
TI Intravenously administrable human **immunoglobulin**
IN Rodolphe, Fritsche; Norbert, Chariatte
PA Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten, Switz.
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 85747	A2	19830817	EP 1982-109362	19821009
	EP 85747	A3	19840905		
	EP 85747	B1	19860514		
	EP 85747	B2	19900530		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 19735	E	19860515	AT 1982-109362	19821009
	ZA 8208687	A	19830928	ZA 1982-8687	19821125
	AU 8291328	A1	19830818	AU 1982-91328	19821208
	AU 554817	B2	19860904		
	FI 8204283	A	19830809	FI 1982-4283	19821214
	FI 73597	B	19870731		
	FI 73597	C	19871109		
	JP 58159424	A2	19830921	JP 1982-217934	19821214
	JP 03065327	B4	19911011		

	ES 518181	A1	19840116	ES 1982-518181	19821214
	DK 8300265	A	19830809	DK 1983-265	19830124
	DK 157367	B	19891227		
	DK 157367	C	19900521		
PRAI	CH 1982-741	19820208			
	EP 1982-109362	19821009			

L7 ANSWER 54 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1983:517678 HCAPLUS
DN 99:117678
TI In-vitro diagnostic method for detection of acetylsalicylic acid ingestion
IN Lopapa, Alberto F.; Hall, Theodore D.
PA Lopapa Institute, Inc., USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4393040	A	19830712	US 1981-246993	19810324

L7 ANSWER 55 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1983:510732 HCAPLUS
DN 99:110732
TI Plasma fractions free of side-effects using fast-reacting antithrombin
IN Eibl, Johann; Elsinger, Fritz; Linnau, Yendra
PA Immuno A.-G. fuer Chemisch Medizinische Produkte, Austria
SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 135,234, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4388232	A	19830614	US 1982-375044	19820505
	AT 359646	B	19801125	AT 1979-2940	19790419
	AT 7902940	A	19800415		
PRAI	AT 1979-2940	19790419			
	US 1980-135234	19800331			

L7 ANSWER 56 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1983:499474 HCAPLUS
DN 99:99474
TI An inter- and intralaboratory quality-control survey of radioimmunoassay of insulin, thyroxine, thyrotropin, cortisol, digoxin, gastrin, .beta.2-microglobulin, and IgE in Japan with commercially available kits
AU Shishiba, Yoshimasa; Irie, Minoru; Yamada, Hideo; Kinoshita, Fumio
CS Div. Endocrinol., Toranomon Hosp., Tokyo, 105, Japan
SO Clin. Chem. (Winston-Salem, N. C.) (1983), 29(8), 1501-7
CODEN: CLCHAU; ISSN: 0009-9147
DT Journal
LA English

L7 ANSWER 57 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1983:70243 HCAPLUS
DN 98:70243
TI Fixation of antigens and antibodies on a polysaccharide support and use of this product for immunological determinations
IN Guerin, Bernard; Lelievre, Daniele
PA Laboratoire Stallergenes, Fr.
SO Fr. Demande, 21 pp.
CODEN: FRXXBL
DT Patent

LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2502786	A1	19821001	FR 1981-5877	19810324
	FR 2502786	B1	19850621		
	EP 63064	A1	19821020	EP 1982-400519	19820323
	EP 63064	B1	19860702		
	R: AT, BE, CH, DE, GB, IT, LU, NL, SE				
	AT 20622	E	19860715	AT 1982-400519	19820323
	JP 58000756	A2	19830105	JP 1982-45729	19820324
PRAI	FR 1981-5877	19810324			
	EP 1982-400519	19820323			

L7 ANSWER 58 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1982:568768 HCAPLUS
DN 97:168768
TI Production and study of a national reference preparation of human blood **immunoglobulins** G, A and M
AU Minakova, L. V.; Malkina, L. A.; Kozlova, N. E.
CS USSR
SO Stand., Shtammy Metody Kontrolya Bakt. Virusn. Prep. (1981), 101-4. Editor(s): Dzagurov, S. G. Publisher: Mosk. Nauchno-Issled. Inst. Vaktsin Syvorotok, Moscow, USSR.
CODEN: 48QNAP
DT Conference
LA Russian

L7 ANSWER 59 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1982:515316 HCAPLUS
DN 97:115316
TI Preparation of native **immunoglobulin** G free of anticomplement activity
IN Acosta Mira, Jose; Navio Lantada, Gloria; Camacho Sompor, Yania
PA Landerlan S. A., Spain
SO Span., 14 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 502788	A1	19820401	ES 1981-502788	19810604
	JP 57206625	A2	19821218	JP 1981-120621	19810731
	DE 3208523	A1	19830505	DE 1982-3208523	19820310
PRAI	ES 1981-502788	19810604			

L7 ANSWER 60 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1982:74549 HCAPLUS
DN 96:74549
TI Column ion-exchange preparation and characterization of an Rh immune globulin (WinRho) for intravenous use
AU Friesen, Albert D.; Bowman, John M.; Price, Hugh W.
CS Winnipeg Rh Inst., Univ. Manitoba, Winnipeg, MB, R3T 2N2, Can.
SO J. Appl. Biochem. (1981), 3(2), 164-75
CODEN: JABIDV; ISSN: 0161-7354
DT Journal
LA English

L7 ANSWER 61 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1981:457449 HCAPLUS
DN 95:57449
TI Detection of proteins in human amniotic fluid using two-dimensional gel electrophoresis

AU Jones, M. I.; Spragg, S. P.; Webb, T.
CS Dep. Chem., Univ. Birmingham, Birmingham, B15 2TT, Engl.
SO Biol. Neonate (1981), 39(3-4), 171-7
CODEN: BNEOBV; ISSN: 0006-3126
DT Journal
LA English

L7 ANSWER 62 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1981:207087 HCAPLUS
DN 94:207087
TI Improvements in production methods for **immunoglobulin** IgG from human plasma
IN Jimenez Sanchez, Maximo Jesus
PA Laboratorios Hubber S. A., Spain
SO Span., 9 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 487853	A1	19801216	ES 1980-487853	19800119

L7 ANSWER 63 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1980:424328 HCAPLUS
DN 93:24328
TI Insolubilized methylated albumin conjugates for autoimmune disease fluoroimmunoassays
IN Rippe, Delfin F.
PA American Hospital Supply Corp., USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8000026	A1	19800110	WO 1979-US310	19790509
	RW: CH, DE, FR, GB				
	US 4234563	A	19801118	US 1978-911865	19780602
	EP 19620	A1	19801210	EP 1979-900670	19790509
	EP 19620	B1	19830907		
	R: CH, DE, FR, GB				
	JP 54158996	A2	19791215	JP 1979-66688	19790529
	ES 481208	A1	19800816	ES 1979-481208	19790601
	US 4251514	A	19810217	US 1979-91619	19791105
	US 4254097	A	19810303	US 1979-90954	19791105
PRAI	US 1978-911865	19780602			

L7 ANSWER 64 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1980:220683 HCAPLUS
DN 92:220683
TI **Immunoglobulin** solution suitable for intravenous use
IN Buenning, Karl
PA Blutspendedienst der Landesverbaende des Deutschen Roten Kreuzes Niedersachsen, Oldenburg und Bremen Gemeinnuetzige G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 2837168	A1	19800306	DE 1978-2837168	19780825
	SE 7906272	A	19800226	SE 1979-6272	19790723
	AT 7905052	A	19820415	AT 1979-5052	19790723
	AT 368886	B	19821125		
	GB 2032437	A	19800508	GB 1979-29104	19790821
	GB 2032437	B2	19821027		
	FR 2433946	A1	19800321	FR 1979-21345	19790824
	JP 55047627	A2	19800404	JP 1979-107315	19790824
	US 4322403	A	19820330	US 1980-189001	19800922
PRAI	DE 1978-2837168	19780825			
	US 1979-67721	19790820			

L7 ANSWER 65 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1980:56611 HCAPLUS
DN 92:56611
TI Stability of the **lyophilized** F(ab')2 fragments of horse tetanus antibodies isolated by affinity chromatography
AU Goch, Halina; Schiller, Barbara; Korbecki, Michal
CS Serum Vaccine Res. Lab., Warsaw, 00-725, Pol.
SO Arch. Immunol. Ther. Exp. (1979), 27(4), 499-509
CODEN: AITEAT; ISSN: 0004-069X
DT Journal
LA English

L7 ANSWER 66 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1979:588722 HCAPLUS
DN 91:188722
TI Isolation and properties of immunoperoxidase complexes
AU Gavrilova, E. M.; Dzantiev, B. B.; Egorov, A. M.
CS Dep. Chem. Enzymol., M. V. Lomonosov Moscow State Univ., Moscow, USSR
SO Biokhimiya (Moscow) (1979), 44(9), 1614-22
CODEN: BIOHAO; ISSN: 0006-307X
DT Journal
LA Russian

L7 ANSWER 67 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1978:480234 HCAPLUS
DN 89:80234
TI **Immunoglobulin** with reduced complement binding
IN Mueller, Hans
PA Behringwerke A.-G., Ger.
SO Ger. Offen., 13 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2658334	A1	19780629	DE 1976-2658334	19761223
	DE 2658334	B2	19800604		
	DE 2658334	C3	19870507		
	NL 7713980	A	19780627	NL 1977-13980	19771216
	NL 190473	B	19931018		
	NL 190473	C	19940316		
	IN 146967	A	19791020	IN 1977-CA1738	19771216
	ES 465180	A1	19790101	ES 1977-465180	19771217
	CH 639394	A	19831115	CH 1977-15668	19771220
	US 4160763	A	19790710	US 1977-862668	19771221
	IL 53670	A1	19801026	IL 1977-53670	19771221
	DK 7705745	A	19780624	DK 1977-5745	19771222
	DK 151610	B	19871221		
	DK 151610	C	19880620		
	SE 7714647	A	19780624	SE 1977-14647	19771222
	BR 7708559	A	19780815	BR 1977-8559	19771222

	AU 7731866	A1	19790628	AU 1977-31866	19771222
	AU 514166	B2	19810129		
	AT 7709227	A	19800415	AT 1977-9227	19771222
	AT 359638	B	19801125		
	CA 1105383	A1	19810721	CA 1977-293679	19771222
	GB 1598080	A	19810916	GB 1977-53480	19771222
	BE 862290	A1	19780623	BE 1977-183818	19771223
	JP 53079023	A2	19780713	JP 1977-155470	19771223
	FR 2375247	A1	19780721	FR 1977-39077	19771223
	FR 2375247	B1	19801128		
	CH 658596	A	19861128	CH 1980-6120	19780101
PRAI	DE 1976-2658334	19761223			
	CH 1977-15668	19771220			

L7 ANSWER 68 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1977:451453 HCAPLUS
DN 87:51453
TI An improved method for the isolation of pure IgG from human serum
CS Peking Metropolitan Hospital, Chronic Bronchitis Res. Team, Biochem. Dep., Peking, Peop. R. China
SO Sheng Wu Hua Hsueh Yu Sheng Wu Wu Li Hsueh Pao (1976), 8(3), 215-24
CODEN: SHWPAU
DT Journal
LA Chinese

L7 ANSWER 69 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1974:410749 HCAPLUS
DN 81:10749
TI Protein electrophoresis of liquor cerebrospinalis with cellulose acetate membranes. I. Comparison of two procedures to **concentrate** proteins of collected liquor cerebrospinalis
AU Kleine, T. O.; Stroh, Maria; Stroh, J.
CS Klin.-Chem. Lab., Univ.-Nervenklin., Marburg/Lahn, Ger.
SO Z. Klin. Chem. Klin. Biochem. (1974), 12(2), 66-72
CODEN: ZKCKAD
DT Journal
LA German

L7 ANSWER 70 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1972:445127 HCAPLUS
DN 77:45127
TI Immunochromatographic purification of human urinary luteinizing hormone
AU Van Hell, H.; Schuurs, A. H. W. M.
CS Biochem. Res. Dev. Lab., N. V. Organon, Oss, Neth.
SO J. Endocrinol. (1972), 54(1), 171-2
CODEN: JOENAK
DT Journal
LA English

L7 ANSWER 71 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1972:32791 HCAPLUS
DN 76:32791
TI Reaction of staphylococcal protein A with rabbit **immunoglobulins**
AU McDowell, Graham; Grov, Arne; Oeding, Per
CS Sch. Med., Univ. Bergen, Bergen, Norway
SO Acta Pathol. Microbiol. Scand., Sect. B (1971), 79(6), 794-800
CODEN: APMIBM
DT Journal
LA English

L7 ANSWER 72 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1971:417800 HCAPLUS
DN 75:17800
TI Preparation of freeze-dried, monomeric and immunochemically pure IgG by

rapid and reproducible chromatographic technique
AU Joustra, Marius; Lundgren, Helga
CS Res. Dep., Pharm. Fine Chem., Uppsala, Swed.
SO Protides Biol. Fluids, Proc. Colloq. (1969), 17, 511-15
CODEN: PBFPA6
DT Journal
LA English

L7 ANSWER 73 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1971:74399 HCAPLUS
DN 74:74399
TI Value of autoradioimmunoelectrophoresis for studies of protein synthesis by lymphocytes in vitro
AU Thiele, H. G.; Stark, R.
CS I. Med. Universitaetsklin., Hamburg, Ger.
SO Z. Immunitaetsforsch., Allerg. Klin. Immunol. (1970), 140(4), 424-7
CODEN: ZIAIAH
DT Journal
LA English

L7 ANSWER 74 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1970:59072 HCAPLUS
DN 72:59072
TI Cleavage of human .gamma. globulin by means of cyanogen bromide
IN Sela, Michael; Arnon, Ruth; Lahav, Miriam
PA United States Dept. of Health, Education, and Welfare
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3466368	A	19690909	US 1967-643165	19670602

L7 ANSWER 75 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1969:113375 HCAPLUS
DN 70:113375
TI Studies on IgA. I. Fractionation procedure for isolation of IgA from pooled normal human plasma
AU Zschocke, Rainer H.; Grieble, Hans G.; Bach, Gerhard L.; Anderson, Truman Oliver
CS Cook County Hosp., Chicago, Ill., USA
SO J. Immunol. (1969), 102(3), 625-37
CODEN: JOIMA3
DT Journal
LA English

L7 ANSWER 76 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1968:10857 HCAPLUS
DN 68:10857
TI Immunoelectrophoretic analysis of soluble proteins from human spleen
AU Bednarik, Tomas; Cajthamlova, H.
CS Inst. Hematol. Blood Transfusion, Prague, Czech.
SO (1967), 16(4), 337-41
DT Journal
LA English

L7 ANSWER 77 OF 77 HCAPLUS COPYRIGHT 2001 ACS
AN 1967:8517 HCAPLUS
DN 66:8517
TI Recovery of long-acting thyroid stimulator from serum of patients with thyrotoxicosis by **concentration** of **immunoglobulin** G
AU Carneiro, L.; Dorrington, Keith J.; Munro, Donald S.

PI US 5102990 19920407
DETD An IgG preparation was made by diluting 0.25 ml of Immune **Globulin** (Human, U.S.P., Cutter Biological, which contained 15-18% protein stabilized with 0.21-0.32M glycine, with 7.25 ml of Sterile Water for Injection, U.S.P., and **filtering** through a 0.22 micron **filter**. 5 ml of the Sn (II) educing solution was mixed with 7.5 ml of the IgG preparation. The vial containing. . . contained the Sn (II), Sn (IV) and other salts, was discarded. The reduced and Sn (II) complexed protein fraction was **concentrated** by ultrafiltration to a **concentration** of 1.7 mg/ml. 0.5 mg aliquots of reduced and Sn (II) complexed protein were placed in sealed, N.sub.2 gas filled serum vials and **frozen**. A Sn (II) pertechnetate reducing solution was made of 0.5 ml of 0.1 mM SnCl.sub.2 in 40 mM potassium biphthalat 10. . . at a pH of 5.6. The Sn (II) pertechnetate reducing solutio was added without allowing the reduced antibody solution to thaw and his solution was also **frozen**. A sterile, 3 mm diameter tin metal shot was added, the vial flushed with N.sub.2 and stored at -20.degree. C.. . .

L19 ANSWER 9 OF 11 USPATFULL
TI Polypeptides and process for the production thereof
PI US 5089400 19920218
DETD . . . are injected i.p. with 2-5.times.10.sup.6 hybridoma cells. Ascitic fluid is collected repeatedly from each mouse. The fluids are pooled and **frozen** at -80.degree. C. After **thawing** the pool is centrifuged at 16.000 rpm for 30 minutes. The fat at the top is sucked off and the supernatant free of debris is saved. When necessary the centrifugation is repeated A crude **immunoglobulin** fraction is obtained from the ascitic fluid by 18% Na.sub.2 SO.sub.4 precipitation at room temperature. Subsequently this fraction is passed. . . through Sephacryl G.200 (Pharmacia) according to manufacturer's instructions using 0,1M Tris-HCI buffer pH 8.2. Active fractions are pooled and **concentrated** by Amicon XM 50 **filters** (Amicon). Protein determination is done by OD.sub.280 measurement assuming that 1 mg of protein gives rise to an absorbance of. . .

L19 ANSWER 10 OF 11 USPATFULL
TI Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
PI US 5078985 19920107
DETD This example illustrates the process of this invention for labeling **immunoglobulin** G (IgG). IgG is obtained obtained from animals such as sheep, goats, mice or humans. Sodium Pertechnetate-Tc-99m U.S.P. is obtained. . . potassium biphthalate and 10 mM sodium tartrate solution (pH 5.6) was added 2 ml of 0.5 M stannous chloride in **concentrated** HCl (12 M). The stannous chloride was prepared by adding the **concentrated** hydrochloric acid to non-oxidized pellets of SnCl.sub.2 having a surface free of dull stannous oxide. The pH of the resultant . . M NaOH to adjust to the final pH. An IgG preparation was made by diluting 0.25 ml of Immune **Globulin** (Human), U.S.P., Biological, which contained 15-18% protein stabilized with 0.21-0.32M glycine, with 7.25 ml of Sterile Water for Injection, U.S.P., and filtering through a 0.22 micron **filter**. 5 ml of the stannous solution was mixed with 7.5 ml of the IgG preparation. The vial containing the admixed. . . was collected and the remaining solute, which contained the stannous and other salts, was discarded. The reduced protein fraction was **concentrated** by ultrafiltration to a **concentration** of 1.7 mg/ml. 0.5 mg aliquots of reduced protein were placed in sealed, N.sub.2 gas filled serum vials and **frozen**. 0.5 ml of 0.1 mM SnCl.sub.2 prepared in 40 mM potassium biphthalate/10 mM sodium tartrate solution, at pH 5.6, was added without allowing the reduced antibody solution to **thaw**, and this solution was also **frozen**.

A sterile, 3 mm diameter tin metal shot was added, the vial flushed with N.sub.2 and stored at minus 20.degree.. . .

L19 ANSWER 11 OF 11 USPATFULL
TI Oligopeptides and intermediates and processes for their manufacture
PI US 4720483 19880119
DETD . . . week, from 2 to 5 ti es.10.sup.6 cloned hybridoma cells are injected intraperitoneally Ascitic fluid is taken repeatedly from each mouse and **frozen** at -20.degree. C. The collected fluid is **thawed** and centrifuged for 30 min. at 4.degree. and 16,000 rev/min. The fat is removed off with suction, and 0.9 volume equivalents of a saturated ammonium sulphate solution are slowly added dropwise, while stirring at 0 degree., to the remaining debris-free supernatant. The resulting crude **immunoglobulin** fraction is passed, using 0.1M tris.HCl (pH 8.2), through Sephacryl G 2000 (Pharmacia) as directed by the manufacturer. Active fractions are combined and concentrated with an Amicon XM50 **fil**

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19538625	A1	19970424	DE 1995-19538625	19951017
DE 19538625	C2	19990812		
WO 9714717	A1	19970424	WO 1996-EP4476	19961015
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 856008	A1	19980805	EP 1996-934688	19961015
EP 856008	B1	20011017		
R: DE, FR, GB				
JP 11514358	T2	19991207	JP 1996-515514	19961015
US 6001974	A	19991214	US 1998-41082	19980310
PRIORITY APPLN. INFO.:			DE 1995-19538625	19951017
			WO 1996-EP4476	19961015

AB Albumin is sepd. and **purified** from human serum in a yield of .gtoreq.84% and a purity of .gtoreq.97% by successive chromatog. on a strongly basic anion-exchange membrane and a strongly acidic cation-exchange membrane. The albumin eluted in the 1st step can be applied to the membrane in the 2nd step without special conditioning. Thus, **frozen** serum was **thawed** at 4.degree., centrifuged at 15,000 g, **filtered** through a microfiltration membrane with pore size 0.45 .mu.m, desalted by gel filtration, adjusted to pH 5.4 to ppt. **euglobulins**, centrifuged at 15,000 g, **frozen, thawed**, centrifuged at 12,000 g, and adsorbed on anion-exchange membrane Sartobind Q 100; impurities were eluted with 25 mM NaOAc buffer (pH 5.4), and albumin was eluted with 50 mM NaOAc buffer (pH 4.5). The eluate was applied directly to cation-exchange membrane Sartobind S 100; impurities were eluted with 50 mM NaOAc buffer (pH 4.5), and albumin was eluted with 25 mM NaOAc buffer (pH 5.4) contg. 150 mM NaCl in 95% yield and 98% purity.

L13 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1985:209419 HCAPLUS
DOCUMENT NUMBER: 102:209419
TITLE: **Purified concentrate** of the group G,A,M serum **immunoglobulins**
INVENTOR(S): Step[illegible]ek, [illegible]an
PATENT ASSIGNEE(S): C[illegible]ch.
SOURCE: C[illegible] 5
C[illegible]ZX
DOCUMENT TYPE: Pa[illegible]
LANGUAGE: [illegible]ze.
FAMILY ACC. NUM. [illegible]OL
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 211239	B	1982[illegible]	CS 1980-4699	19800702

AB Aq. **Ig** solns. were co[illegible]d. by s[illegible]ionary freezing and **thawing** and used as [illegible]e puti[illegible] gel. [illegible]. Thus, a 2-5% soln. of conventional **Ig** [illegible]pt. [illegible]ed. [illegible]rogen-free water was dialyzed against an aq. NaCl [illegible]n of [illegible]**red** through gel to remove low-mol.-wt. compds. Th[illegible]s [illegible]as sterilized, gradually **frozen** in a metal column at -[illegible]de[illegible]e. [illegible] -5.degree. in 2-24 h, and **thawed** in 2-48 h at [illegible]-temp. [illegible]q. **conc.** was batchwise collect[illegible]. [illegible]e co[illegible]mn. Wit[illegible] anal. control until the protein **concn.** dropped to [illegible]

L13 ANSWER 5 OF [illegible] AB[illegible]O RI[illegible]01 ACS

Factor VIII with 25.4 times higher activity than that of the original plasma. Fibrinogen was pptd. by addn. of polyethylene glycol (PEG) and then sepd., and the Factor VIII was pptd. by addn. of more PEG. The pptd. Factor VIII was washed with 1.8-M glycocoll, dissolved in tris-Na citrate buffer, **filter**-sterilized, placed in dosage units, and **freeze**-dried. When the dried product was reconstituted to the same vol. with H2O, the soln. contained 25-30 Factor VIII units/mL (3 units/mg protein), and only 0.048 mg fibrinogen/mg protein.

L13 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:513666 HCAPLUS
DOCUMENT NUMBER: 79:113666
TITLE: Biochemical studies on cachexia due to cancer. I. Partial purification and properties of the hypoalbuminemic substance from Ehrlich solid carcinoma
AUTHOR(S): Kubota, Yukiho; Ueki, Hiroshi; Shoji, Shozo; Shigematsu, Hidenari
CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
SOURCE: Yakugaku Zasshi (1973), 93(7), 887-92
CODEN: YKKZAJ
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB A hypoalbuminemic substance was extd. from mouse Ehrlich solid carcinoma. The tumors were homogenized with saline, centrifuged, and the resultant turbid supernatant (F-1) was sepd. The turbidity was removed by freezing and **thawing** of the supernatant, and the resultant clear ext. (F-2) was dialyzed against 12mM NaCl. The inner soln. (possessing hypoalbuminemic activity) was **freeze**-dried. This fraction (F-3) was gel-**filtered** through Sephadex G-150, by using 12mM NaCl followed by M HOAc contg. 12mM NaCl as the eluant. An active fraction (F-4-II) was gel-**filtered** again under the same condition. Of 4 peaks obtained, the third was the active fraction (F-5-III). The yield in protein was 3.0% for F-1 and 0.2% for F-5-III. The decrease in serum albumin was statistically significant for F-1 and F-5-III, while the changes in serum **globulins** were not significant. F-5-III did not produce a significant change in total serum protein. F-5-III was not electrophoretically homogeneous, although it sedimented as a single peak in ultracentrifugal anal. Its mol. wt. was roughly estd. to be 16,000 by ultracentrifugation. The amino acid content of F-5-III was 59.95%, and aspartic acid, glutamic acid, and **isoleucine** were present in fairly large amts. Neither the ext. prepd. from the gluteus maximus of a normal mouse by the same procedures nor bovine serum albumin had hypoalbuminemic activity.

L13 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:122436 HCAPLUS
DOCUMENT NUMBER: 78:122436
TITLE: Therapeutic concentrate of coagulation factors II, IX, and X from citrated, factor VIII-depleted plasma
AUTHOR(S): Middleton, Sarah M.; Bennett, Ida H.; Smith, J. K.
CORPORATE SOURCE: Scott. Natl. Blood Transfus. Assoc., R. Infirm., Edinburgh, Scot.
SOURCE: Vox Sang. (1973), 24(5), 441-56
CODEN: VOSAAD
DOCUMENT TYPE: Journal
LANGUAGE: English

AB DEAE-cellulose (1 kg, Whatman DE 32) was equilibrated with 0.5N HCl; water (to pH >4); 0.5N NaOH; water (to pH <8); 1.0N NaCl; water (to cond. <1 .mu.mho) and stirred for 90 min at 2.degree. with 120 l. of Cohn fraction I supernatant (from pooled ACD plasma) dild. with 40 l. of water. After centrifugation in a Sharples centrifuge, the supernatant was processed for **IgG** and albumin, while the absorbent was stirred with 41 (cooled to 5.degree.)of 0.03M NaH2PO4, 0.03M Na citrate, pH 6.9. cond. 9 mmho, ionic strength 0.24, and poured into a column of diam. 150-225 mm

(preautoclaved). The column was washed further with 4 l. of the same buffer and eluted with 6 l. of 0.2M NaCl in the same buffer (cond. 20 mM, ionic strength 0.44). Factors II, IX, and X, which emerged after the salt front, were collected in 400 ml fractions, assayed, pooled to 30 units of factor IX/ml, **frozen, thawed, filter** -sterilized, and lyophilized in 10 ml doses. Reconstituted doses contained 0.6-1.2 g% protein, pH 6.8-7.1, 210-280m- M Ns, 40-90mM citrate, 20-50mM phosphate, 5-20mM Cl; cond. was 13 mmho, and osmolarity, 320 mosmolar. Factors II, IX, and X were 250-300-fold **concd.**, recovered in 79% yield (range 42-105%). Although the material was pyrogenic in rabbits, this effect might have been due to heteroagglutinins; no pyrogenic reactions were obsd. in 30 patients receiving a total of 120 doses at 30-50 units kg during hemorrhage, and 20-30 units/kg for maintenance. The half-life of administered factor IX was 24-48 hr.

L13 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:14417 HCAPLUS
DOCUMENT NUMBER: 78:14417
TITLE: Antigen extracts of animal thymocytes and specie-specific antithymocytic serums and .gamma.-globulins
INVENTOR(S): Goret, Pierre; Toma, Bernard; Salmon, Henri
PATENT ASSIGNEE(S): Laboratoires Albert Rolland
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2205897	A	19720824	DE 1972-2205897	19720208
DE 2205897	C3	19800522		
DE 2205897	B2	19790830		
GB 1342391	A	19740103	GB 1971-4276	19710209
CH 538866	A	19730831	CH 1972-1244	19720128
BE 778754	A1	19720531	BE 1972-113451	19720131
ES 399465	A1	19750116	ES 1972-399465	19720203
CA 955849	A1	19741015	CA 1972-134005	19720204
RO 61514	P	19761215	RO 1972-69679	19720204
IL 38704	A1	19741231	IL 1972-38704	19720207
DK 132104	B	19751027	DK 1972-527	19720207
NO 137308	B	19771031	NO 1972-311	19720207
ZA 7200825	A	19721025	ZA 1972-825	19720208
FI 50203	B	19750930	FI 1972-344	19720208
NL 7201683	A	19720811	NL 1972-1683	19720209
AT 316743	B	19740625	AT 1972-1039	19720209

PRIORITY APPLN. INFO.: GB 1971-4276 19710209

AB Thymus antigens with stability on long storage are injected into animals of species different than the antigen donor for the prepn. of species-specific anti-thymocyte sera and .gamma.-**globulins**. Cellular suspensions from the thymus or the bursa of fabricius of birds are **filtered** through a series of sieves or through gauze, **frozen** at -20 to -40.deg., stored at this temp. and dispersed for use by **thawing** and movement through closely packed 51/8 mm diam. spherical .od[illegible]. The antigen is injected into animals of a species different than the antigen donor and the collected serum is **purified** by adsorption on [illegible]ol prepd. from the protein obtained from the liver and [illegible]er of the antigen donor or a similar animal, and 5% by wt. glutaraldehyde soln. .gamma. **Globulins** are also prepd. from the anti-thymocytic serum.

=> d query l11;d ibib abs tot
L11 2001179 SEA FILE=HCAPLUS ABB=ON PLU=ON CONCEN?

L13 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:577986 HCAPLUS
DOCUMENT NUMBER: 132:34468
TITLE: Improved methods for the separation and **purification** of **immunoglobulin** from egg yolk by filtration and one step anion-exchange chromatography
AUTHOR(S): Li, Jian-Cai; Chen, Tian-Bao; Zhang, Rong-Zhen; Chen, Ru-Ming; Li, Long; Rao, Ping-Fan
CORPORATE SOURCE: Institute of Biotechnology, Fuzhou University, Fujian, 350002, Peop. Rep. China
SOURCE: Food Health Pac. Rim, Int. Conf. Food Sci. Technol., 3rd (1999), Meeting Date 1997, 384-390. Editor(s): Whitaker, John R. Food & Nutrition Press: Trumbull, Conn.
CODEN: 68BQAF
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Reported in this paper is an improved method for **isolation** of antibodies by filtration and anion-exchange chromatog. from egg yolk. Egg yolk was dild. 7 times with distd. water without pH adjustment and then **frozen** at -10.degree.C. The **frozen** dild. egg yolk was then **thawed** at 15.degree.C. Celite was added to the dild. egg yolk prior to filtration to facilitate the process. The dild. yolk soln. was then **filtered** through cellulose acetate **filters** with pore size of 0.22 um at 15.degree.C. An industrially feasible filtration velocity was achieved with the system, hundreds of times faster than reported data. A clear water-sol. fraction (WSF) contained approx. 15-18% by wt. of antibodies compared to the wt. of total proteins obtained. The WSF was then adjusted to contain 75 mM sodium phosphate buffer, pH 6.8, and applied to a DEAE-Toyopearl 650M column. The electrophoretically pure **IgY** was obtained in the eluate eluted with 150 mM sodium phosphate buffer, pH 6.8. It is a method most likely to be developed into a com. scale process to produce **IgY** suitable for industrial applications in terms of cost and scale.
REFERENCE COUNT: 19
REFERENCE(S):
(1) Akita, E; J Food Sci 1992, V57, P629 HCAPLUS
(2) Bucolo, G; Clin Chem 1973, V19, P476 HCAPLUS
(3) Fichtali, J; Biotechnol Bioengin 1992, V40, P1388 HCAPLUS
(5) Hatta, H; Agric Biol Chem 1990, V54, P2531 HCAPLUS
(7) Horikoshi, T; J Food Sci 1993, V58(4), P739 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:72617 HCAPLUS
DOCUMENT NUMBER: 130:213644
TITLE: Dried biologically or therapeutically active preparations
INVENTOR(S): Kanellos, Jerry; Oates, Adrian; Goss, Neil
PATENT ASSIGNEE(S): CSL Limited, Australia
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910011	A1	19990304	WO 1998-AU682	19980825
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9807633	A	19990225	ZA 1998-7633	19980824
AU 9887231	A1	19990316	AU 1998-87231	19980825
EP 1009438	A1	20000621	EP 1998-938550	19980825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			AU 1997-8719	19970825
			WO 1998-AU682	19980825

AB A dried, heat-treated product comprises (i) a heat labile, biol. or therapeutically active protein or peptide prepn. and (ii) a stabilizing effective amt. of a compn. comprising sucrose, trehalose and at least one amino acid. The protein or peptide prepn. may be, for example, a factor VIII **conc.** or a von Willebrand Factor **conc.** Fresh **frozen** plasma (FFP) is **thawed** at temps. below 5.degree. and the FVIII-rich cryoppt. is collected by centrifugation. The FVIII is extd. with Tris buffer. Levels of unwanted proteins, principally fibrinogen, fibronectin, **Ig** and albumin, are reduced by pptn. with heparin followed by repptn. of FVIII with sodium chloride/glycine buffer. The **purified** FVIII is redissolved in a sodium chloride-Tris-citrate buffer contg. sucrose and a low level of calcium chloride. The dissolved ppt. is **filtered**, treated with solvent/detergent and incubated. The mixt. is then **filtered** and chromatographed on a Sephacryl S400 column pre-equilibrated in the same buffer. The FVIII-rich eluate (>50 IU/mg total protein) is then **concd.** by ultrafiltration against the same buffer and chem. stabilizers added to the retentate. The bulk formulated **conc.** is sterile **filtered**, dispensed, **freeze** dried and heat treated at 80.degree. for 72 h. The **freeze** drying cycle proceeds under conditions of programmed temp./vacuum/timing for approx. 100 h. The formulated product is loaded into a **freeze** dryer and the shelves cooled to -50.degree.. The vacuum is applied and the temp. ramped up to -5[illegible].degree.. The finished lyophilized product is then heated in a hot air oven at 80.degree. for 72 h.

REFERENCE COUNT: 10

REFERENCE(S):
(1) Asahi Chem Ind Co Ltd; JP 05331071 A 1993 HCAPLUS
(2) Asahi Chem Ind Co Ltd; JP 06321805 A 1994 HCAPLUS
(3) Behringwerk Aktiengesellschaft; US 4297344 A 1981 (CAPLUS
(4) Behringwerk Aktiengesellschaft; US 4562072 A 1985 [illegible]PLUS
(5) Baxter Laboratories Inc; US 4623717 A 1986 HCAPLUS

[illegible]L CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 199[illegible]32145 HCAPLUS
DOCUMENT NUMBER: 126[illegible]97652
TITLE: Method for [illegible]paration of albumin from serum by [illegible]chromatography with membrane adsorbents
INVENTOR(S): [illegible]Wolfgang; Nussbaumer, Dietmar; Kula, M[illegible]a[illegible]egi; Thoemmes, Joerg; Gebauer, Klaus-Heinrich
PATENT ASSIGNEE(S): Sartorius Ag, Germany
SOURCE: Ger. Offen., 5 pp.
COD[illegible]: G[illegible]XBX

L13 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:59953 HCAPLUS
DOCUMENT NUMBER: 77:59953
TITLE: A hypoalbuminemic substance from Ehrlich solid carcinoma
AUTHOR(S): Kubota, Yukiho; Ueki, Hiroshi; Shigematsu, Hidenari
CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
SOURCE: Gann (1972), 63(2), 277-8
CODEN: GANNA2
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The tumors were homogenized with saline and centrifuged at 15,000 rpm for 30 min; the turbid supernatant (F-1) was sepd., the turbidity was removed by repeated freezing and **thawing** followed by centrifugation, and the resulting clear supernatant (F-2) was dialyzed against 12 mM NaCl soln. The inner soln. possessing hypoalbuminemic activity was **freeze**-dried. This fraction (F-3) was gel-**filtered** through Sephadex G-150, using 12 mM NaCl soln. as eluant. Of the 4 peaks obtained, the 3rd was the active fraction (F-4III). For its assay, the samples were given to dd-K mice by a daily i.p. injection for 6 days. Serum albumin and **globulins** were detd. by densitometry of the electrophoregram of the serum on cellulose acetate paper. A decrease in serum albumin was statistically significant for F-1 and F-4-III, while the changes in total serum protein or serum **globulins** were not significant. The hydrolysate of F-4-III consisted of hexose, hexosamine, and 18 kinds of amino acids, in which aspartic acid, glutamic acid, and **isoleucine** were contained in fairly large amts. (>10% each). Neither the ext. prepd. from gluteus maximus muscle of a normal mouse by the same procedures nor bovine serum albumin displayed hypoalbuminemic activity.

L13 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1967:8300 HCAPLUS
DOCUMENT NUMBER: 66:8300
TITLE: Preparation of **purified** antihemophilic **globulin** and a study of its properties
AUTHOR(S): Rozenberg, G. Ya.; Rutberg, R. A.; Novoselova, V. N.; Blinova, M. A.; Papush, N. D.
CORPORATE SOURCE: Central Inst. Hematol. and Blood Transfusion, Moscow, USSR
SOURCE: Probl. Gematol. Pereliv. Krovi (1966), 11(10), 3-8
CODEN: PGPKA8
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Mix fresh human blood (450 ml.) with 50 ml. 3.8% di-Na citrate and 0.003% levomycetin (1:9), centrifuge twice at 4.degree. and 1600-1800 rpm. for 20 and 30 min., resp. **Freeze** the plasma immediately at -35.degree. and keep at this temp. for 1-2 weeks. **Thaw** it at + 10.degree. for 1-3.3 hrs., decrease its temp. (2-3.degree.) to 0.degree., and centrifuge at this temp. for 40 min. and 1800 rpm. Use the supernatant, which is free from the main part of antihemophilic **globulin** (AHG), for the prepn. of fibrinogen (I) and other protein prepns. Dissolve the ppt. from 1 l. of plasma in 80 ml. of distd. apyrogenic water (total vol. about 90 ml.), add 10 ml. sterile Al(OH)3 gel, mix vigorously, and let stand for 15-18 hrs. Centrifuge at 1800 rpm. for 40 min. at 0.degree., sep. the supernatant, add 20 ml., i.e., 2% of the initial vol. of buffer soln. (21.25 g. NaCl, 12.5 g. glucose, and 5 g. di-Na citrate in 500 ml. water, pH 6.5-6.7), and **filter** through a plastic **filter**, **freeze**, and lyophilize. One l. of blood plasma yielded 100-110 ml. AHG soln. To **purify** it, take the supernatant after Al(OH)3 removal, add slowly and dropwise EtOH to final **concn**. of 20% (the temp. must not exceed 0.degree.), let stand 1 hr., and centrifuge at 0.degree. and 1800 rpm. for 40 min. Dissolve the ppt. in buffer soln. (0.2 g. di-Na citrate, 0.8 g. NaCl, and 0.5 g.

glucose in 100 ml. water, pH 6.5-6.7) (10% vol. of the initial plasma), and lyophilize. A 12-15-fold enrichment of AHG was reached. The crude prepn. contained about 250 mg. % I, albumin <250 mg. %, but pptn. with EtOH removed it (simultaneously a 30% decrease of AHG activity occurred). Since no prepn. was pyrogenic or toxic (tested on rabbits, 1 ml./kg., and mice, 0.5 ml./mouse), 50-100 ml. of the prepn. was given 5 times to 4 patients with hemophilia, with successful results.

=> d his l7-

(FILE 'HCAPLUS' ENTERED AT 10:25:54 ON 08 MAR 2001)
E E58+OLD
E IMMUNO GLOBULIN/CT
E IMMUNOGLOBULIN/CT
E E93+ALL
E E103+ALL
E IMMUNOGLOBULINS/CT
E E107+ALL
L7 190743 S ?GLOBULIN? OR POLYGLOBIN? OR IG OR IG## OR E138-E154 OR BENCE
L8 72406 S FREEZE? OR FROZ?
L9 14925 S THAW?
L10 238456 S FILTER?
L11 2001179 S CONCEN?
L12 7 S L7 AND L8 AND L9 AND L10 AND L11
L13 11 S L7(L)(ISOL? OR PURIF? OR L11) AND L8 AND L9 AND L10

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	127.86	171.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.35	-12.94

FILE 'USPATFULL' ENTERED [illegible] 10:52:5. ON 08 MAR 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2001 (20010306/PD)
FILE LAST UPDATED: 6 Mar 2001 (20010306/ED)
HIGHEST PATENT NUMBER: US6199207.
CA INDEXING IS CURRENT THROUGH 6 Mar 2001 (20010306/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2001 (20010306/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2000
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2000

>>> Page images are availab[illegible]or [illegible]t nts from 1/1/1997. Current <<<
>>> week patent text is typi[illegible]y [illegible]ded by Thursday morning and <<<
>>> page images are available [illegible]r di[illegible]lay by the end of the day. <<<
>>> Image data for the /FA fi[illegible]d [illegible]e [illegible]vai[illegible]able the following week. <<<

>>> Complete CA file [illegible]ndexing [illegible]c[illegible]ical patents (or equivalents) <<<
>>> is included in fi[illegible] [illegible]ord[illegible]. P[illegible]esauri is available for the <<<
>>> USPTO Manual of C[illegible]si[illegible]ticn[illegible]. /NCL, /INCL, and /RPCL <<<
>>> fields. This thes[illegible]ri[illegible]s [illegible]lu[illegible] catchword terms from the <<<
>>> USPTO/MOC subject he[illegible] [illegible]ar[illegible] bheadings. Thesauri are also <<<
>>> available for the FI[illegible] [illegible]ri[illegible] al Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, [illegible]e /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, [illegible]pec[illegible]ely. The thesauri in <<<
>>> the /IC5 and /IC fields inclu[illegible]he corresponding catchword <<<
>>> terms from the IPC [illegible]bject head[illegible]s and subheadings. <<<

This file contains CAS Regist[illegible]y Numbers for easy and accurate

substance identification.

```
=> s l7(p)(isol? or purif? or l11)(p)l8(p)l9(p)l10
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L7(P)(ISOL?'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L11)(P)L8'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L8(P)L9'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L9(P)L10'
         21952 ?GLOBULIN?
             0 POLYGLOBIN?
          9218 IG
           332 IGS
          9406 IG
                 (IG OR IG.
         32336 IG##
            70 IGA/CT
             5 IGA1/CT
             3 IGA2/CT
             8 IGD/CT
            62 IGE/CT
           233 IGG/CT
             0 "IGG AUTOANTIBODIES"/CT
             7 "IGG CONJUGATES"/CT
            82 IGG1/CT
            16 IGG2/CT
            20 IGG2A/CT
             9 IGG2B/CT
            12 IGG3/CT
            11 IGG4/CT
            94 IGM/CT
             0 "IGM AUTOANTIBODIES"/CT
             3 IGY/CT
           134 BENCE
             1 BENCES
           135 BENCE
                 (BENCE OR BENCES)
         18603 JONES
        109513 PROTEIN
           108 BENCE-JONES PROTEIN?
                 (BENCE(W)JONES(W)PROTEIN?)
        390807 ISOL?
        210332 PURIF?
        748745 CONCEN?
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTE
L14        3344 L7(P ,IS  ). PUR  OR L11)(P 8(P)L9(P)L10

=> s l7(s)(isol? or pur  l1 )  (s)l9(s)l10
PROXIMITY OPERATOR LEVEL  NS1  WITH
FIELD CODE - 'AND' OPERATOR  ED 'L7(S)(ISOL?'
PROXIMITY OPERATOR LEVEL NOT  STENT  ITH
FIELD CODE - 'AND' OPERATOR  'L11)(S)L8'
PROXIMITY OPERATOR LEvel NOT  TEN  WITH
FIELD CODE - 'AND' OPER OR  S  'L  S)L9'
PROXIMITY OPERATOR LEVE NOT  TEI  WITH
FIELD CODE - 'AND' OPERATOR  S  'L9(S)L10'
         21952 ?GLOBULIN?
             0 POLYGLOBI
          9218 IG
```

ACCESSION NUMBER: 1982:488019 HCAPLUS
DOCUMENT NUMBER: 97:88019
TITLE: **Isolation** and **purification** of human **thyroglobulin**
AUTHOR(S): Lu, Fengxian; Yang, Cuipo; Tong, Zhigang; Tang, Te; Znang, Tiangeng; Wang, Renming; Li, Yan
CORPORATE SOURCE: Dep. Pathol., Tianjin Med. Coll., Tianjin, Peop. Rep. China
SOURCE: Tianjin Yiyao (1980), 8(1), 8-11
CODEN: TIYADG
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Human thyroid tissue was **frozen** at -20.degree., **thawed**, sectioned, and 100 g of sectioned tissue was treated with 300 mL saline contg. a few drops of 0.3% PhMe and kept in a refrigerator overnight. The ext. was **filtered**, **concd.**, and centrifuged at 4000 rpm for 30 min to give a supernatant which was passed through a Sephadex G 200 column. A fraction contg. **thyroglobulin** was collected, **concd.**, and again passed through a Sephadex G 200 column with a saline eluent. The active fraction was collected, distributed into ampuls, and **freeze** dried. A yield of 1.5 g **thyroglobulin**/100 g tissue was obtained. The product was **purified** further by ion-exchange chromatog. The sedimentation coeff. (S20,w) was 14.0 for **thyroglobulin** from deceased normal subjects but was 14.3 for that from patients with hyperthyroidism.

L13 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:27788 HCAPLUS
DOCUMENT NUMBER: 88:27788
TITLE: **Purified** antihemophilic **globulin** A (factor VIII)
INVENTOR(S): Ida, Toshiro; Shiga, Masashi
PATENT ASSIGNEE(S): Green Cross Corp., Japan
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2715832	A1	1977 [illegible]	DE 1977-2715832	19770407
DE 2715832	B2	1979[illegible]		
DE 2715832	C3	19[illegible]		
JP 52125609	A2	1[illegible]	JP 1976-39894	19760409
JP 55012890	B4	1980[illegible]		
US 4093608	A	1978[illegible]	US 1977-783625	19770401
PRIORITY APPLN. INFO.			JP 1976-39894	19760409

AB **Purified** antihemophilic **globulin** A (factor VIII [9001-27-8]) is obtained from fresh or pooled human plasma by use of a weakly basic (diethylaminoethyl dextran (DEAE dextran) ion exchanger. The stability and solv. of the factor VIII are also increased and the prothrombin complex and fibrinogen contents are decreased using this method. For example, a [illegible] from human plasma (contg. 1.3 .times. 106 units total prothrombin activity and 1.3 .times. 106 units total Factor VIII activity) was **thawed**, pooled, adjusted to 4.degree., pH 7.4, and [illegible] mV/cm elec. cond., and stirred with preswollen (pH 7.[illegible]) sterilized DEAE-Sephadex A-50 [39455-31-7]. The [illegible] plasma-loaded dextran was sepd., removing 96.5% of the prothrombin. To the remaining plasma at 0 to -2.degree. to a **concn** of [illegible], and the plasma was centrifuged to sep. Factor VIII as a cryoppt. The ppt. was extd. with a tris-Na citrate buffer (pH 7.4) to give a crude soln. contg. a 75.3% yield of

```
            16 IGG2/CT
            20 IGG2A/CT
             9 IGG2B/CT
            12 IGG3/CT
            11 IGG4/CT
            94 IGM/CT
             0 "IGM AUTOANTIBODIES"/CT
             3 IGY/CT
           134 BENCE
             1 BENCES
           135 BENCE
                 (BENCE OR BENCES)
         18603 JONES
        109513 PROTEIN?
           108 BENCE-JONES PROTEIN?
                 (BENCE(W)JONES(W)PROTEIN?)
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTER?
        748745 CONCEN?
L16       3294 L7(S)L8(S)L9(S)L10(S)L11

=> d hit

L16  ANSWER 1 OF 3294  USPATFULL
SUMM   One of the preferred methods for introducing DNA into a plant cell by
       means of Agrobacterium is the so-called leaf disk transformation using
       Agrobacterium [Horsch et al (1985)]. Sterile leaf disks from a suitable
       target plant are incubated with Agrobacterium cells comprising one of
       the GA 20-oxidase-encoding DNA sequence according to the invention, and
       are then transferred into or onto a suitable nutrient medium. Especially
       suitable, and therefore preferred within the scope of this invention,
       are LS media that have been solidified by the addition of agar and
       enriched with one or more of the plant growth regulators customarily
       used, especially those selected from the group of the auxins consisting
       of a-naphthylacetic acid, picloram, 2,4,5-trichlorophenoxyacetic acid,
       2,4-dichlorophenoxyacetic acid, indole-3-butyric acid, indole-3-lactic
       acid, indole-3-succinic acid, indole-3-acetic acid and
       p-chlorophenoxyacetic acid, and from the group of the cytokinins
       consisting of kinetin, 6benzyladenine, 2-isopentenyladenine and zeatin.
       The preferred concentration of auxins and cytokinins is in the
       range of from 0.1 mg/l to 10 mg/l.

DETD   50 to 500 mg/ml of DNA fragments are added to a reaction batch in the
       buffer recommended by the manufacturer, New England Biolabs. The
       reaction batch contains all four deoxynucleotide triphosphates in
       concentrations of 0.2 mM. The reaction takes place over a period
       of 30 minutes at 15 C and is then terminated by heating at 65 C for 10
       minutes. For fragments obtained by cleaving with restriction
       endonucleases that produce 5'-projecting ends, such as EcoRI and BamHI,
       the large fragment, or Klenow fragment, of DNA polymerase is used. For
       fragments obtained by means of endonucleases that produce 3'-projecting
       ends, such as PstI and SacI, the T4 DNA polymerase is used. The use of
       these two enzymes is described on pages 113 to 121 of the Maniatis et al
       (1982) reference.
DETD   The extracted DNA is first treated with restriction enzymes, then
       subjected to electro-phoresis in a 0.8% to 1% agarose gel, transferred
       to a nitrocellulose membrane [Southern E. M. (1975)] and hybridised with
       the DNA to be detected which has previously been subjected to
       nick-translation (DNA-specific activities of 5.times.10.sup.8 to
       10.times.10.sup.8 c.p.m/mg). The filters are washed three
       times for 1 hour each time with an aqueous solution of 0.03 M sodium
       citrate and 0.3 M sodium chloride at 65 C. The hybridised DNA is made
```

```
          332 IGS
         9406 IG
                (IG OR IGS)
        32336 IG##
           70 IGA/CT
            5 IGA1/CT
            3 IGA2/CT
            8 IGD/CT
           62 IGE/CT
          233 IGG/CT
            0 "IGG AUTOANTIBODIES"/CT
            7 "IGG CONJUGATES"/CT
           82 IGG1/CT
           16 IGG2/CT
           20 IGG2A/CT
            9 IGG2B/CT
           12 IGG3/CT
           11 IGG4/CT
           94 IGM/CT
            0 "IGM AUTOANTIBODIES"/CT
            3 IGY/CT
          134 BENCE
            1 BENCES
          135 BENCE
                (BENCE OR BENCES)
        18603 JONES
       109513 PROTEIN?
          108 BENCE-JONES PROTEIN?
                (BENCE(W)JONES(W)PROTEIN?)
       390807 ISOL?
       210332 PURIF?
       748745 CONCEN?
        60200 FREEZE?
        51396 FROZ?
        20426 THAW?
       546264 FILTER?
L15      3344 L7(S)(ISOL? OR PURIF? OR L11)(S)L8(S)L9(S)L10

=> s  l7(s)(isol? or purif? or l11)(s)l8(s)l9(s)l10
=> s  l7(s)l8(s)l9(s)(s)l11
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L7(S)L8'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L8(S)L9'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L9(S)L10'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L10(S)L11'
        21952 ?GLOBULIN?
            0 POLYGLOBIN
         9218 IG
          332 IGS
         9406 IG
                (IG OR IGS
        32336 IG##
           70 IGA/CT
            5 IGA1/CT
            3 IGA2/CT
            8 IGD/CT
           62 IGE/CT
          233 IGG/CT
            0 "IGG AUTOANTIBODIES"/CT
            7 "IGG CONJUGATES"/CT
           82 IGG1/CT
```

```
=> s  ?globulin?(s)l8(s)l9(s)l10(s)l11
         21952 ?GLOBULIN?
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTER?
        748745 CONCEN?
L19         11 ?GLOBULIN?(S)L8(S)L9(S)L10(S)L11

=> d ti pn kwic tot

L19  ANSWER 1 OF 11  USPATFULL
TI     Process for the manufacture of thrombin inhibitors
PI     US 5728549  19980317
DETD   . . . one week, 2 to 5.times.10.sup.6 cloned hybridoma cells are
       injected intraperitoneally. Ascitic fluid is repeatedly taken from each
       mouse and frozen at -80 degree. C. The accumulated fluid is
       thawed and centrifuged for 30 minutes at 4.degree. C. and 16,000
       revs/min. The fat is filtered off with suction and 0.9 volume
       equivalents of a saturated ammonium sulphate solution is slowly added
       dropwise, while stirring at 0.degree. C., to the remaining debris-free
       supernatant. The resulting crude immunoglobulin fraction is
       passed through Sephacryl G 2000 (Pharmacia) using 0.1 mM tris.HCl (pH
       8.2), in accordance with the instructions of the manufacturer. Active
       fractions are combined and concentrated with Amicon XM50
       filter (Amicon).

L19  ANSWER 2 OF 11  USPATFULL
TI     Cryptosporidium hybrid vector and transformed host cells
PI     US 5643772  19970701
DETD   For SDS-PAGE, 2.times.10.sup.9 oocysts were lysed by 5 cycles of
       freeze-thawing in 1% Triton Buffer (150 mM Na Cl; 100
       mM EDTA; and 1% Triton X-100), in the presence of protease. . . for 8
       hrs. (Petersen, C., et al., "Characterization of an Mr>900,000
       Cryptosporidium parvum Sporozoites Glycoprotein Recognized by
       Hyperimmune Bovine Colostral Immunoglobulin", Inf. & Immun.
       60(12):5132 (1992)). Western blots were incubated with HBC Ig (lot
       #40529) (dil 1/500) in 20 ml PBS. . . "Cryptosporidium parvum
       (Apicomplexa: Cryptosporidiidae) Oocyst and Sporozoite Antigens
       Recognized by Bovine Colostral Antibodies", Inf. Imm. 58:2966 (1990)).
       Eluted antibodies were filter sterilized and
       concentrated to a final volume of 1 ml in a Centriprep 10
       concentrator (Amicon, Mass.).

L19  ANSWER 3 OF 11  USPATFULL
TI     Direct radiolabeling of antibodies and other proteins with technetium or
       rhenium
PI     US 35500  19970506
       US 5102990  19920407 (original)
DETD   An IgG preparation was made by diluting 0.25 ml of Immune
       Globulin (Human), [illegible] Biological, which contained
       15-18% protein stabilized with 0.21-0.32M glycine, with 7.25 ml of
       Sterile Water for [illegible], and filtering through a
       0.22 micron filter. [illegible] the Sn (II) reducing solution was
       mixed with 7.5 ml of [illegible] preparation. The vial containing. . .
       contained the Sn (II), Sn (IV) and other salts, was discarded. The
       reduced and Sn (II) complexed protein fraction was concentrated
       by ultrafiltration to a concentration of 1.7 mg/ml. 0.5 mg
       aliquots of reduced and Sn (II) complexed protein were placed in sealed,
       N.sub.2 gas filled [illegible] and frozen. A Sn (II)
       pertechnetate reducing solution was made of 0.5 ml of 0.1 mM SnCl.sub.2
       in 40 mM potassium biphthalate/ . . . at a pH of 5.6. The Sn (II)
       pertechnetate reducing solution was added without allowing the reduced
```

antibody solution to **thaw**, and this solution was also **frozen**. A sterile, 3 mm diameter tin metal shot was added, the vial flushed with N.sub.2 and stored at -20.degree. C.. . .

L19 ANSWER 4 OF 11 USPATFULL
TI Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
PI US 35457 19970218
US 5078985 19920107 (Original)
DETD This example illustrates the process of this invention for labeling **immunoglobulin** G (IgG). IgG is obtained from animals such a sheep, goats, mice or humans. Sodium Pertechnetate-Tc-99m U.S.P. is obtained from. . . potassium biphthalate and 10 mM sodium tartrate solution (pH 5.6) was add.d 0.2 ml of 0.5 M stannous chloride in **concentrated** HCl (12 M). The stannous chloride was prepared by adding the **concentrated** hydrochloric acid to non-oxidized pellets of SnCl.sub.2 having a surface free of dull stannous oxide. The pH of the resultant. . . 1 M NaOH to adjust to the final pH. An IgG preparation was made by diluting 0.25 ml of Immune **Globulin** (Human), U.S.P., Cutter Biological, which contained 15-18% protein stabilized with 0.21-0.32 M glycine, with 7.25 ml of Sterile Water for Injection. U.S.P., and **filtering** through a 0.22 micron **filter**. 5 ml of the reducing solution was mixed with 7.5 ml of the IgG preparation. The vial containing the admixed. . . was collected and the remaining eluate, which contained the stannous and other salts, was discarded. The reduced protein fraction was **concentrated** by ultrafiltration to a **concentration** of 1.7 mg/ml. 0.5 mg aliquots of reduced protein were placed in sealed, N.sub.2 gas filled serum vials and **frozen**. 0.5 ml of 0.1 mM SnCl.sub.2 prepared in 40 mM potassium biphthalate/10 mM sodium tartrate solution, at pH 5.6 was added without allowing the reduced antibody solution to **thaw**, and this solution was also **frozen**. A sterile, 3 mm diameter tin metal shot was added, the vial flushed with N.sub.2 and stored at m us 20.degree.. . .

L19 ANSWER 5 OF 11 USPATFULL
TI Method of producing an anti- immunoglobulin concentrate and a pharmaceutical preparation
PI US 5593675 19970114
SUMM With the method according to the invention, **immunoglobulin** can be obtained directly from human plasma. The starting material is the plasma from Rh-negative donors sensitized to the rhesus factor D. The individual donations obtained through plasmapheresis is preferably **frozen** and carefully **thawed** at 0.degree.-4.degree. C. before fractionation, and pooled. The plasma pool should contain more than 10 .mu.g anti-D I[illegible] per ml, . . . the cation exchange chromatography can be carried preliminarily using any known method, such as, for example, by precipitation of the **cryoglobulins** or by fractionated precipitation by means of ethanol (Cohn, E. J. et al. J. Am. Chem. Soc. 68, 45[illegible]; Kistler and Nitschmann, H. Vox Sang. 7, 414, 1962), by other precipitation methods, such as precipitation of the **immunoglobulins** by ammonium sulfate, sodium sulfate, polyethylene glycol, caprylic acid or rivanol, or by a chromatographic method or a combination of such methods. Prior to the cation exchange chromatography according to the invention, the **cryoglobulin** -free plasma or the plasma fraction containing **immunoglobulin** dissolved in the equilibration buffer is preferably **filtered**, and to inactivate hidden viruses it is treated with a biocompatible, organic solvent such as, for example, tri(n-butyl) phosphate and. . . detergent is then treated 37.degree. C. A phase separation takes place thereby. The clear lower phase is separated, diluted, **filtered**, and adjusted to the equilibration conditions of the cation exchange chromatography, the temperature for the subsequent steps

being, as a. . . detergents used for virus inactivation are likewise removed here. The anti-D IgG of the IgG subclasses 1 and 3 specifically **concentrated** by this process step is eluted by the ion exchange gel by increasing conductivity to preferably over 10 mS/cm. The. . . less than 15% of the total IgG fraction and has a changed IgG subclass spectrum: IgG1 and IgG3 are strongly **concentrated**, IgG2 and IgG4 are greatly reduced. This anti-D IgG fraction is then purified further by treatment with a second, weakly. . . diethylaminoethyl (DEAE) as functional group, anti-D IgG not being bound to the ion exchangers under the selected conditions. To increase **concentration**, the purified anti-D IgG fraction is preferably bound a second time to a CM ion exchange gel and is eluted as **concentrated** as possible under suitable conditions, and is manufactured into the final product. For achieving the conditions according to the invention it is not of significance whether the anti-D IgG fraction is eluted by increasing the ionic **concentration**, or by pH shift or by a buffer changed in composition. To reduce the **concentration** of further undesired components, such as, for example, proteases, the **immunoglobulin** solution can be treated additionally with an adsorbent, such as, for example, aluminum hydroxide gel, during any stage of the. . .

L19 ANSWER 6 OF 11 USPATFULL
TI Process for the manufacture of thrombin inhibitors
PI US 5422249 19950600
DETD . . . one week, 2 to 3.times.10.sup.6 cloned hybridoma cells are injected intraperitoneally. Ascitic fluid is repeatedly taken from each mouse and **frozen** at -80.degree. C. The accumulated fluid is **thawed** and centrifuged for 30 minutes at 4.degree. C. and 16,000 revs/min. The fat is **filtered** off with suction and 0.9 volume equivalents of a saturated ammonium sulphate solution is slowly added dropwise, while stirring at 0.degree. C. to the remaining debris-free supernatant. The resulting crude **immunoglobulin** fraction is passed through Sephacryl S 2000 (Pharmacia) using 0.1 mM tris.HCl (pH 8.2), in accordance with the instructions of the manufacturer. Active fractions are combined and **concentrated** with Amicon XM50 **filter** (Amicon).

L19 ANSWER 7 OF 11 USPATFULL
TI Direct radiolabeling of substrates containing monosulfides or disulfide bonds with radionuclides
PI US 5277893 19940111
DETD An IgG preparation was made by diluting 0.25 ml of Immune **Globulin** (Human), U.S.P., Hyland Biological, which contained 15-18% protein stabilized with 0.21-0.32 M glycine, with 7.25 ml of Sterile Water for Injection U.S.P., and **filtering** through a 0.22 micron **filter**. 5 . . . of the Sn (II) reducing solution was mixed with 7.5 ml of the IgG preparation. The vial containing. . . contained the Sn (II), [illegible] and other salts, was discarded. The reduced and Sn (II) complexed protein fraction was **concentrated** by ultrafiltration to a **concentration** of 1.7 mg/ml. 0.5 mg aliquots of reduced, Sn (II) complexed protein were placed in sealed, N.sub.2 gas filled [illegible] vials and **frozen**. A Sn (II) pertechnetate reducing solution was made of 0.5 ml of 0.1 Mm SnCl.sub.2 in 40 mM potassium biphthalate, 10. . . at a pH of 5.6. The Sn (11) pertechnetate reducing solution was added without allowing the reduced antibody solution to thaw, and this solution was also **frozen**. A sterile, [illegible] glass bead tin metal shot was added, the vial flushed with [illegible] and stored at -20.degree. C.. . .

L19 ANSWER 8 OF 11 USPATFULL
TI Direct radiolabeling of antibodies and other proteins with technetium or rhenium

visible by blackening an X-ray film over a period of 24 to 48 hours.

DETD An oligo(dT)-primed cDNA library was constructed in .lambda.gt11 (Amersham) using cotyledon mRNA. The total library (70,000 clones) was amplified to give 3.6.times.10.sup.8 plaque forming units (pfu)/ml of which 69% were recombinant. Immunoscreening of the amplified library was performed with 3,600 pfu on one 90 mm plate and probing with the 20-oxidase peptide antibody (1 mg/ml) and an alkaline phosphatase-conjugated anti-rabbit **IgG** second antibody.

DETD When the protein was incubated at increasing **concentrations** with [.sup.14 C] GA.sub.12 (Table 1A) sequential oxidation of the C-20 methyl group to the alcohol, aldehyde and carboxylic acid occurred to give, respectively, radiolabelled GA.sub.15, GA.sub.24 and GA.sub.25 as products. The corresponding 13-hydroxy GA products (GA.sub.44, GA.sub.19 and GA.sub.17) were also obtained, although at lower efficiency, when the lysate was incubated with [.sup.14 C] GA.sub.53 (Table 1B). A comparison of the aldehyde substrates GA.sub.24 (non-hydroxylated), GA.sub.19 (monohydroxylated) and GA.sub.23 (dihydroxylated), showed that the efficiency of oxidation to the corresponding tricarboxylic acids decreased with increasing polarity of the substrate (Table 1C). In addition, the corresponding C.sub.19 -GA products (GA.sub.9, GA.sub.20 and GA.sub.1), which are formed by loss of C-20 as CO.sub.2, were obtained in low yield. The results indicate that a single enzyme may catalyse each of the steps involving oxidation at C-20 during GA biosynthesis, possibly also including the loss of C-20, although confirmation of this must await studies with the corresponding enzyme from a plant tissue in which C.sub.19 -GA production forms a major pathway.

DETD Explants roughly 5 to 10 mm are cut from young leaves 3 to 5 cm long and third to sixth from the apex of N. tabacum cv `Xanthi nc` grown under axenic conditions [Facciotti and Pilet, 1979] in solid MS medium [Murashige and Skoog, 1962] containing 0.7% phytagar (Gibco-BRL), 1 mg/l IAA, 0.15 mg/l kinetin. These explants are plated on solid MS medium containing 0.6% phytagar, 40 mg/l adenine sulfate, 2 mg/l IAA, and 2 mg/l kinetin on the surface of which is placed a #1 Whatman **filter** and incubated for 24 hr in the dark at 24 C. Agrobacterium strains containing the binary vectors described above are grown overnight in LBMG at 30 C on a shaker at 180 rpm. Explants are dipped into a bacterial suspension of 3.3.times.10.sup.8 cells/ml for approximately 5 minutes, blotted on sterile paper towels, and re-plated on the same plates. After 48 hours explants are placed on selection medium containing the same plate medium as above plus 350 mg/l cefotaxime and 100 mg/l kanamycin. Co-cultivated control tissue is placed on the same medium but without kanamycin. The explants are transferred to fresh media every two weeks. Shoots are harvested 4 to 8 weeks after co-cultivation placed on 50 ml culture tubes with 25 ml of solid MS medium containing 0.8% phytagar, 1 mg/l IBA, 350 mg/l cefotaxime, and 100 mg/l kanamycin. All tissue is grown at 24 C to 28 C, 12 hours of light, 12 hours dark, light intensity 6700 to 8400 l .times.. Shoots root in 1 to 2 weeks and are then transplanted to planting mix in 4" pots and placed in the "transgenic plant phytotron".

DETD 1 to 1.5 ml PCV of the suspension culture cells from above are incubated in 10 to 15 ml of a **filter** sterilized mixture consisting of 4% cellulase RS with 1% Rhozyme in KMC (8.65 g/l KCl, 16.47 g/l MgCl.sub.2.6H.sub.2O, 1.47 g/l CaCl.sub.2.2H.sub.2 O, pH 5.6) salt solution. Digestion is carried out at 30 C on a slow rocking table for a period of 3 to 4 hours. The preparation is monitored under an inverted microscope for protoplast release. The protoplasts which are released are collected as follows:

DETD The preparation is **filtered** through a 100 mm mesh sieve, followed by a 50 mm mesh sieve. The protoplasts are washed through the sieves with a volume of KMC salt solution equal to the original volume of enzyme solution. 10 ml of the protoplast preparation is placed in each of several disposable plastic centrifuge tubes, and 1.5 to 2 ml of 0.6 M sucrose solution (buffered to pH 5.6 with 0.1% MES and KOH)

layered underneath. The tube is centrifuged at 60 to 100.times.g for 10 minutes, and the protoplasts banding at the interface collected using a pipette and placed in a fresh tube. The protoplast preparation is resuspended in 10 ml of fresh KMC salt solution, and centrifuged for five minutes at 60 to 100.times.g. The supernatant is removed and discarded, and the protoplasts resuspended gently in the drop remaining, and then 10 ml of a 13/14 strength KMC solution gradually added. After centrifuging again for five minutes, the supernatant is again removed and the protoplasts resuspended in a 6/7 strength KMC solution. An aliquot is taken for counting, and the protoplasts again sedimented by centrifugation. The protoplasts are resuspended at 10.sup.7 per ml in KM-8p medium or in 0.5 M mannitol containing 6 mM MgCl.sub.2 or other suitable medium for use in transformation as described in the following examples. This protoplast suspension is used for transformation and is cultured as described below.

DETD A. The protoplasts are resuspended at the last step of above in a 0.5 M mannitol solution containing 12 to 30 mM MgCl.sub.2. A heat shock of 45.degree. C. for five minutes is given as describes The protoplasts are distributed in aliquots for transformation in centrifuge tubes, 0.3 ml of suspended protoplasts per tube. During the next 10 minutes the following are added: DNA and PEG solution (MW 6000, 40% containing 0.1 M Ca(NO.sub.3).sub.2 and 0.4 M mannitol; pH 8 to 9 with KOH) to give a final **concentration** of 20% PEG. The aliquots are incubated for 30 minutes with occasional gentle shaking, and then the protoplasts are placed in petri dishes (0.3 ml original protoplast suspension per 6 cm diameter dish) and cultured as described.

DETD C. The above is repeated with the modification that the final **concentration** of PEG is between 13 and 25%.

DETD Protoplasts are prepared from embryogenic suspension cultures of above by aseptically **filtering** the cells on a Nalgene 0.2 mm **filter** unit and then adding 0.5 g fresh weight cells to each 12.5 ml of protoplasts enzyme mixture in a petri dish. The enzyme mixture consists of cellulase RS, 7 mM CaCl.sub.2 xH.sub.2 O, 0.7 mM NaH.sub.2 PO4xH.sub.2 O, 3 mM MES (pH 5.6), glucose (550 mOs/kg H.sub.2 O of pH 5.6), and is **filter** sterilized. The mixture is swirled on an orbital shaker at about 50 rpm in dim (<420 l.times.) light for about 4 to 5 hours. The digest is then sieved through a stainless steel sieve (100 mm mesh size) and distributed into 12 ml centrifuge tubes which are centrifuged at about 60 to 100.times.g for about 5 minutes. The protoplast-containing sediment is then washed three times with protoplast culture medium KM-8p adjusted to 550 mOs/kg H.sub.2 O with glucose. At this point a flotation step may be included for further purification of the protoplasts. In this case, the washed protoplasts are layered atop 10 ml KM-8p culture medium adjusted to 700 mOs/kg H.sub.2 O with sucrose. After centrifugation at 60 to 100.times.g for about 10 minutes, protoplasts banding at the interface are collected using a fine pipette. Finally the protoplasts are resuspended in 1 to 2 ml KM-8p culture medium and sieved through a stainless steel screen (20 mm mesh size). The protoplasts released are collected and washed and resuspended in KM-8p medium for culture or in osmotically adjusted medium suitable for transformation according to the examples below.

DETD A. The purified protoplasts are plated at a density of about 5.times.10.sup.5 protoplasts per ml in KM-8p culture medium containing 1.3% SeaPlaque agarose (FMC Corp., Marine Colloids Division, Rockland, Me., USA) and 30 to 40% conditioned medium (obtained from 3 to 4 week-old Dactylis glomerata L. embryogenic suspension cultures by **filtering** the medium through a sterile Nalgene 0.2 mm **filter**, making the medium 55 mOs/kg H.sub.2 O by addition of glucose, and again **filtering** sterilizing). The plates are then placed in the dark at room temperature of 28.degree. C. After 10 to 14 days the agarose is cut into wedges and placed into `bead culture` as described by Shillito et al. (1993) using 20 ml SH-45 suspension culture medium with 3% sucrose per 3 ml original agarose embedded culture. The plants are put on a platform shaker and agitated at about

50 rpm in light at 670 1.times.. New suspension cultures are formed as the colonies grow out of the agarose and release cells into the liquid medium. The resultant suspension cultured cells are plated onto agar-solidified SH-30 medium and placed in the dark at 25.degree. C. until callus is formed.

DETD A. Immediately after purification of the protoplasts, electroporation is performed according to Shilito et al (1985) using linezed plasmid The protoplasts are resuspended after the last wash at a density of about 7.times.10.sup.6 protoplasts per ml in the electroporation buffer (0.4 M mannitol, 6 mM MgCl.sub 2). The protoplasts are placed in 0.7 ml aliquots in 10 ml plastic centrifuge tubes. Plasmid DNA and sonicated calf thymus DNA (Sigma) to give final **concentrations** of 10 mg/ml and 50 mg/ml respectively is added to the tubes. Then 0.38 ml PEG solution [24% PEG 6000 in 0.4 M mannitol, 30 mM MgCl.sub.2, 0.1% MES (H 5.6)] is added and the solution gently mixed. The protoplast suspension is transferred into the chamber of a Dialog Electroporator and 10 pulses of 3250 Vcm.sup.-1 initial voltage and exponential decay constant of 10 msec applied at 30 sec intervals. The sample is removed from the chamber, and placed in a 10 cm diameter petri dish. 10 ml of KM-8p medium containing 1.2% SeaPlaque agarose is added, the protoplasts distributed evenly throughout the medium, and the agarose allowed to gel.

DETD The cells are given a plasmolysis treatment before bombardment. Packed cell volume is measured and cells are diluted in 1 MS liquid medium with added osmoticum: 0.4 M sorbitol for suspension cells and 0.6 M sorbitol for callus cells. Cells are diluted such that the final packed cell volume per target is 1/20 ml for a fine suspension and 1/10 ml for callus. Diluted cells are placed in a 250 ml flask containing a stir bar and are stirred for a minimum of 30 minutes, up to a few hours. To plate the cells, 2 ml is withdrawn from the flask and pipetted into the top of a vacuum flask onto which a Whatman 2.5 cm GFA **filter** has been placed. The vacuum is applied until the cells are dried onto the **filter**, the **filters** are placed on 60.times.15 mm petri plates containing 5 ml of solid post bombardment plasmolysis medium: 1MS containing 0.2 M sorbitol for suspension cells, or 0.4 M sorbitol for callus cells. Two **filters** are plated on each dish.

DETD Bombarding of cell cultures is carried out using a device as described in EP-A . . . . Invert the petri plate containing the cell **filters** onto the platform on top of the stage, centered over the particle flight opening. Place the clear lid over the top of the platform. Place a microprojectile onto the breech pin and close the breech. Push the "arm" button to fill the reservoir with the appropriate amount of helium gas (usually 1800-1900 psi). Pull the vacuum on the chamber to .sup. about 25 mm. Turn off the vacuum, and push the "arm" and "fire buttons. Move the "arm" button on the "off" position. Each **filter** is usually shot twice.

DETD After bombardment the cells are kept in the dark overnight. The next day, **filters** are removed from plasmolysis medium and placed on 1MS medium. Selection is applied 7-10 days post-bombardment for suspension cells and later days for callus cells. Cells are scraped off the **filters** and spread onto the surface of plates containing 1MS plus an appropriate selection agent, dependent on the selection marker gene used in plant transformation. Plates are incubated in the dark for several weeks. Resistant colonies that arise after a few weeks are transferred to 1MS + selection agent. Coloni that continue to proliferate for about 3-4 weeks are then transferred to "0.5 MS" maintenance medium: MS salts, vitamins, iron, 3% sucrose, 0.7% agar, 0.5 mg/liter 2,4-D. Tissue is subcultured onto this medium biweekly until embryogenic structures or tissue seems suitable for regeneration.

DETD Seeds of Arabidopsis thaliana var Landsberg erecta are surface sterilised by treatment with 5% sodium hypochlorite solution in 0.01% Tween-20 (Sigma), washed three times in water and suspended in 0.15% agar. The seeds are sown onto 0.8% agar containing Murashige and Skoog Medium supplemented with vitamins (Sigma) and 5% sucrose in sterile Magenta

by autoradiography against Kodak X-OMAT AR film with intensifying screens, overnight at -70.degree. C.

DETD The insert of pAt2204 is labelled with .sup.32 P-dCTP and used to probe nitrocellulose **filter** lifts of a full-length cDNA library, constructed in .lambda.ZapII (Stratagene) from poly-A.sup.4 RNA isolated from shoot material of the gibbereffin-deficient gal mutant of Arabidopsis thaliana (Koornneef M and van der Veen J H (1980)). The hybridisation is carried out in 50% fromamide, 50 mM sodium phosphate pH 6.3, 0.75 M NaCl, 75 mM sodium citrate, 0.1% bovine serum albumin, 0.1% Ficoll 400, 0.1% polyvinylpyrrolidone 360, 0.1% sodium dodecyl sulphate and 100 .mu.g/ml salmon testes DNA at 42.degree. C. overnight **Filters** are washed in 15 mM NaCl, 1.5 mM sodium citrate at 42.degree. C. for 10 min. Hybridising plaques are identified by autoradiography and purified by successive rounds of hybridisation. Positive clones are converted into pBluescript clones by plasmid rescue and characterised by EcoRI digestion and DNA sequencing. Clone pAt2353 and clone pAt2301, containing a 1.3 kbp insert, are chosen for heterologous expression studies

DETD The 1.3 kbp insert of pAt2301 is excised with EcoRI, purified by agarose gel electrophoresis and ligated to expression vector pTrcHisA (Invitrogen), previously digested with EcoRI and dephosphorylated. Ligation products are introduced into E. coli strain TOP10 (Invitrogen) by transformation and selected by growth on 2.times. YT agar with ampicillin at 100 .mu.g/ml. Plasmid DNA is isolated from a number of the resulting clones and the orientation of the cDNA insert determined by HindIII digestion. Clone pAt2328 contained a cDNA insert in sense orientation, and is used to inoculate 50 ml of 2.times. YT containing carbenicillin at 100 .mu.g/ml. After 2 hrs growth shaking at 37.degree. C., IPIG (Isopropyl-b-D-thiogalactopyranoside) is added to 1 mM and the cultures are grown for a further 5 hrs. The cells are collected by centrifugation and suspended in 4 ml of 100 mM Tris-Cl pH7.5, 4 mM DTT and sonicated on ice for a total of 90 secs. The samples are then **frozen** in liquid nitrogen, **thawed** by hand and insoluble material removed by centrifugation at 15,000.times.g for 5 min. The resulting supernatant material is stored at -80.degree. C. and subsequently used for enzyme assay.

=>
<------User Break--- -->

=> s l17(p)l8(p)l9(p)l10(p)l11
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L7(P)L8'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L8(P)L9'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L9(P)L10'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L10(P)L11'
21952 ?GLOBULIN?
0 POLYGLOBIN?
9218 IG
332 IGS
9406 IG
(IG OR IGS)
32336 IG##
70 IGA/CT
5 IGA1/CT
3 IGA2/CT
8 IGD/CT
62 IGE/CT
233 IGG/CT
0 "IGG AUTOANTIBODIES"/CT

containers (Sigma). Plants are grown for 4 weeks at 20.degree. C. and shoot material is **frozen** in liquid nitrogen and stored at -70.degree. C. Genomic DNA is isolated essentially as described by Murray and Thompson (Murray MG and Thompson WF (1980)). The **frozen** tissue, 10 g, is ground to a slurry in an ice-cooled mortar with a small amount of acid-washed sand. The homogenate is transferred to a polypropylene centrifuge tube and an equal volume of 2% (w/v) CTAB (cetyltrimethylammonium bromide, Sigma), 1.4M NaCl, 0.1 M Tris-Cl pH8.0, 20 mM EDTA added . After gentle mixing, the tube is incubated at 67.degree. C. for 20 min with occasional mixing. The tube is removed from the water bath and 0.5 volumes of chloroform added, mixed gently and left at room temperature (20.degree. C.) for 20 min with occasional inversion. The tube is centrifuged at 2000 g for 5 min at room temperature, the upper phase removed to a new tube and the lower phase discarded. To the upper phase is added 0.1 vol of 10% (w/v) CTAB, 0.7M NaCp and the chloroform extraction above is repeated. The upper phase is again decanted to a new tube and 2 volumes of 1% (w/v) CTAB, 50 mM Tris-Cl, pH8.0, 10 mM EDTA added. This is mixed gently and left at room temperature for 1 hour, then centrifuged at 5000 mg for 5 min. The pellet is dissolved in 50% (w/w) CsCu in TB, buffer with ethidium bromide at 0.5 mg/mid. The solution is transferred to a Quick-seal tube (Beckman) and centrifuged in a vertical rotor (Beckman VTi90) for 16 hours at 80,000 rpm at 20.degree. C. The DNA is visualised under natural light and removed with the aid of a syringe and nee. Ethidium bromide is removed by extraction four times with 5 volumes of butan-1-ol, previously equilibrated against NaCI-saturated water. The solution is diluted by the addition of 3 volumes of TB buffer (10 mM Tris-Cl pH8.0, 1 mM EDTA) and DNA precipitated with 2 volumes of EtOH. The DNA is pelleted by centrifugation at 10,000 g for 10 min at 0.degree. C., washed with 70% ETOH, dried in vacuo, and dissolved in TE buffer. The DNA **concentration** is determined by its absorbance at 260 nm.

DETD A 50 ml aliquot of 2.times. YT (1.6% Bactotryptone, 1% yeast extract, 0.5% NaCl) including 0.2% maltose and 10 mM MgSO.sub.4 is inoculated with a single colony of E coli XL1-Blue. This is gown overnight at 30 C, transferred to a sterile centrifuge tube and spun down at 2000.times.g for 5 min, room temperature. The cells are resuspended in 10 Mm MgSO.sub.4. In sterile 15 ml tubes, 500 ml E. coli cells is mixed with 50,000 recombinant bacteriophage from the amplified library and incubated at at room temperature for 10 min followed by 37 C for 15 min. Molten top agarose (0.75% in 2.times. YT/0.2% maltose/10 mM MgSO.sub.4), 6.5 ml, is added at 48 C and the tube contents quickly poured onto a prewarmed 10 cm.times.10 cm plate of 1.5% agar in 2.times. YT/0.2% maltose/10 mM MgSO.sub.4. The plates are incubated inverted at 37 C for 6 hours and then stored overnight at 4.degree. C. Duplicate nitrocellulose **filters** are labelled and placed onto the agar plates for 1 min each. The **filters** are air dried and treated for 5 min each in 1.5 M NaCl, 0.5M NaOH (denaturation); 3M NaCl, 1M Tris-Cl pH 6.5 (neutralization); 0.6M NaCl, 60 mM trisodium citrate (fixation). The filters are then air dried on **filter** paper and baked in vacuo, between layers of **filter** paper, at 80 C for 2 hrs.

DETD Nitrocellulose **filters** prepared as above are wetted in water and prehybridized for 2 hours at 42.degree. C. in hybridization buffer (50% formamide, 50 mM NaPi pH 6.3, 0.75 M NaCl, 75 mM trisodium citrate, 0.1% (w/v) bovine serum albumin, 0.1% (w/v) Ficoll 400, 0.1% (w/v) polyvinylpyrrolidon, 0.1% (w/v) sodium dodecyl sulphate (SDS), 100 mg/ml sonicated fish sperm DNA). The probe is boiled for 2 min, mixed with 25 ml prehybridization buffer and sealed into a polythene bag with the prehybridized **filters**. Hybridization is carried out at 42.degree. C. overnight. The unbound probe is removed by washing in 0.3 M NaCl, 30 mM trisodium citrate, 0.1% (w/v) SDS at room temperature for 15 min, and in 15 mM NaCl, 1.5 mM trisodium citrate, 0.1% SDS at 60.degree. C. for 30 min. Positively-hybridizing plaques are identified

```
             7 "IGG CONJUGATES"/CT
            82 IGG1/CT
            16 IGG2/CT
            20 IGG2A/CT
             9 IGG2B/CT
            12 IGG3/CT
            11 IGG4/CT
            94 IGM/CT
             0 "IGM AUTOANTIBODIES"/CT
             3 IGY/CT
           134 BENCE
             1 BENCES
           135 BENCE
                 (BENCE OR BENCE?)
         18603 JONES
        109513 PROTEIN?
           108 BENCE-JONES PROTEIN?
                 (BENCE(W)JONES(W)PROTEIN?)
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTER?
        748745 CONCEN?
L17       3294 L7(P)L8(P)L9(P)L10(P)L11

=> s  ?golulin?(s)l8(s)l9(s)l10(s)l11
             0 ?GOLULIN?
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTER?
        748745 CONCEN?
L18           0 ?GOLULIN?(S)L8(S)L9(S)L10(S)L11

=> s  ?globulin?(s)l8(s)l9(s)l10(s)l11
         21952 ?GLOBULIN?
         60200 FREEZE?
         51396 FROZ?
         20426 THAW?
        546264 FILTER?
        748745 CONCEN?
L19          11 ?GLOBULIN?(S)L8(S)L9(S)L10(S)L11
```

CS Dep. Pharm. Therap., Univ. Sheffield, Sheffield, Engl.
SO Clin. Sci. (1966), 31(2), 215-21
CODEN: CSCIAE
DT Journal
LA English

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	106.34	106.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.18	-1.18

FILE 'STNGUIDE' ENTERED AT 15:16:11 ON 21 MAR 2001

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 16, 2001 (20010316/UP).

=>
=>